

2022 Medicines in Development – Chronic Diseases

Alzheimer's Disease

<u>Drug Name</u>	<u>Organization</u>	<u>Indication</u>	<u>Development Phase</u>
ABBV-916	AbbVie North Chicago, IL	Alzheimer's disease	Phase II www.abbvie.com
ACU193 (amyloid beta-protein inhibitor)	Acumen Pharmaceuticals Charlottesville, VA	Alzheimer's disease	Phase I www.acumenpharm.com
AD-35 (amyloid-beta aggregation inhibitor)	Hisun USA Bridgewater, NJ	Alzheimer's disease	Phase II www.hisunusa.com
AD101 (calcium channel antagonist)	AmyriAD Therapeutics Los Angeles, CA	Alzheimer's disease	Phase II www.amyriadtherapeutics.com
AKST/GRF6019 (neurogenesis stimulant)	Alkahest San Carlos, CA Grifols Barcelona, Spain	mild to moderate Alzheimer's disease, severe Alzheimer's disease	Phase II www.alkahest.com
AL001 (neuron modulator)	Alzamed Neuro Atlanta, GA	Alzheimer's disease	Phase II www.alzamed.com

Alzheimer's Disease

<u>Drug Name</u>	<u>Organization</u>	<u>Indication</u>	<u>Development Phase</u>
AL002 (TREM2 enhancer)	AbbVie North Chicago, IL Alector South San Francisco, CA	Alzheimer's disease	Phase II www.abbvie.com
AL003 (CD33 antigen inhibitor)	AbbVie North Chicago, IL Alector South San Francisco, CA	Alzheimer's disease	Phase I completed www.abbvie.com
ALN-APP (amyloid beta-protein modulator)	Alnylam Pharmaceuticals Cambridge, MA Regeneron Pharmaceuticals Tarrytown, NY	early-onset Alzheimer's disease	Phase I www.alnylam.com www.regeneron.com
ALX-001 (mGluR5 modulator)	Allyx Therapeutics New Haven, CT	Alzheimer's disease	Phase I www.allyxthera.com
ALZ-801 (valiltramiprosate) (amyloid beta-protein inhibitor)	Alzheon Framingham, MA	early Alzheimer's disease (APOE4/4 homozygotes) (Fast Track)	Phase III www.alzheon.com
		early Alzheimer's disease (APOE4 carriers)	Phase II www.alzheon.com

Alzheimer's Disease

<u>Drug Name</u>	<u>Organization</u>	<u>Indication</u>	<u>Development Phase</u>
ALZT-OP1 (amyloid beta-protein inhibitor/ inflammation mediator inhibitor)	AZTherapies Boston, MA	early Alzheimer's disease	Phase III completed www.aztherapies.com
AMX0035 (sodium phenylbutyrate/ tauroursodeoxycholic acid)	Amylyx Pharmaceuticals Cambridge, MA	Alzheimer's disease	Phase II completed www.amylyx.com
ANAVEX®2-73 (blarcamesine) (muscarinic receptor agonist/ sigma-1 receptor agonist)	Anavex Life Sciences New York, NY	Alzheimer's disease	Phase II/III www.anavex.com
ANVS301 (amyloid beta-protein inhibitor)	Annovis Bio Berwyn, PA	Alzheimer's disease	Phase I www.annovisbio.com
APH-1104 (protein kinase C stimulant)	Aphios Woburn, MA	Alzheimer's disease	Phase I www.aphios.com
APNmAb005 (tau protein inhibitor)	Aprinoia Therapeutics Taipei, Taiwan	Alzheimer's disease	Phase I www.aprinoia.com
AR1001 (PDE5 inhibitor)	AriBio San Diego, CA	Alzheimer's disease	Phase II completed www.aribio.com

Alzheimer's Disease

<u>Drug Name</u>	<u>Organization</u>	<u>Indication</u>	<u>Development Phase</u>
atuzaginstat (COR388) (peptide hydrolase inhibitor)	Cortexyme South San Francisco, CA	Alzheimer's disease	Phase II www.cortexyme.com
bepranemab (RG6416) (tau protein inhibitor)	Roche/Genentech South San Francisco, CA	Alzheimer's disease	Phase II www.roche.com
BIIB076 (tau protein inhibitor)	Biogen Cambridge, MA	Alzheimer's disease	Phase I www.biogen.com
BIIB080 (tau protein inhibitor)	Biogen Cambridge, MA	Alzheimer's disease	Phase I www.biogen.com
BIIB113 (O-GlcNAcase inhibitor)	Biogen Cambridge, MA	Alzheimer's disease	Phase I www.biogen.com
BPN14770 (zatolmilast) (PDE4D inhibitor)	Tetra Discovery Partners Grand Rapids, MI Shionogi Florham Park, NJ	Alzheimer's disease	Phase II www.tetradiscovery.com www.shionogi.com
bryostatin-1 (protein kinase C stimulant)	Synaptogenix New York, NY	Alzheimer's disease	Phase II www.synaptogen.com
crenezumab (RG7412) (amyloid beta-protein inhibitor)	Roche/Genentech South San Francisco, CA	familial Alzheimer's disease in healthy people	Phase II www.roche.com

Alzheimer's Disease

<u>Drug Name</u>	<u>Organization</u>	<u>Indication</u>	<u>Development Phase</u>
CT1812 (sigma-2 receptor antagonist)	Cognition Therapeutics Purchase, NY	mild to moderate Alzheimer's disease (Fast Track)	Phase II www.cogrx.com
		early Alzheimer's disease	Phase I www.cogrx.com
CY6463 (sGC stimulant)	Cyclerion Therapeutics Cambridge, MA	Alzheimer's disease	Phase I/II www.cyclerion.com
donanemab (N3pG-Ab mAb)	Lilly Indianapolis, IN	early Alzheimer's disease (Breakthrough Therapy)	application submitted www.lilly.com
		preclinical Alzheimer's disease	Phase III www.lilly.com
E2006 (orexin receptor antagonist)	Eisai Nutley, NJ	Alzheimer's disease dementia	Phase II www.eisai.com
E2511 (synapse regenerant)	Eisai Nutley, NJ	Alzheimer's disease	Phase I www.eisai.com
E2814 (tau protein inhibitor)	Eisai Nutley, NJ	Alzheimer's disease	Phase II/III www.eisai.com

Alzheimer's Disease

<u>Drug Name</u>	<u>Organization</u>	<u>Indication</u>	<u>Development Phase</u>
EI-1071 (CSF-1R inhibitor)	Elixiron Immunotherapeutics Shanghai, China	Alzheimer's disease	Phase I www.elixiron.com
fosgonimeton (ATH-1017) (HGF/c-met stimulant)	Athira Pharma Bothell, WA	Alzheimer's disease	Phase III www.athira.com
gantenerumab (RG1450) (amyloid beta-protein inhibitor)	Roche/Genentech South San Francisco, CA	prodromal to mild Alzheimer's disease (Breakthrough Therapy), early Alzheimer's disease	Phase III www.roche.com
GV-971 (amyloid beta-protein inhibitor)	Green Valley Pharmaceuticals Shanghai, China	Alzheimer's disease	Phase III www.greenvalleypharma.com
Ilaris [®] canakinumab	Novartis Pharmaceuticals East Hanover, NJ	Alzheimer's disease	Phase II www.novartis.com
JNJ-3657 (anti-tau mAb)	Janssen Research & Development Raritan, NJ	Alzheimer's disease	Phase II www.janssen.com
JNS108 (oral trans-resveratrol)	Jupiter Neurosciences Palm Beach Gardens, FL	Alzheimer's disease	Phase II www.jupiterneurosciences.com
KarXT (M1-M4 muscarinic agonist)	Karuna Therapeutics Boston, MA	psychosis in Alzheimer's disease	Phase II www.karumatx.com

Alzheimer's Disease

<u>Drug Name</u>	<u>Organization</u>	<u>Indication</u>	<u>Development Phase</u>
KFRX01 (nilotinib BE) (tyrosine kinase inhibitor)	KeifeRx McLean, VA	Alzheimer's disease	Phase III www.keiferx.com
lecanemab (amyloid beta protein inhibitor)	Biogen Cambridge, MA Eisai Nutley, NJ	early Alzheimer's disease (Breakthrough Therapy) (Fast Track)	application submitted www.biogen.com www.eisai.com
		preclinical Alzheimer's disease	Phase III www.biogen.com www.eisai.com
LM11A-31 (p75 neurotrophin receptor)	Pharmatrophix Menlo Park, CA	Alzheimer's disease	Phase II completed www.pharmatrophix.com
Lu AF87908 (tau protein inhibitor)	Lundbeck Deerfield, IL	Alzheimer's disease	Phase I www.lundbeck.com
LX1001 (AAV-mediated gene therapy)	Lexeo Therapeutics New York, NY	Alzheimer's disease (Fast Track)	Phase I www.lexeotx.com
LY3372689 (O-GlcNAcase inhibitor)	Lilly Indianapolis, IN	Alzheimer's disease	Phase II www.lilly.com
masupirdine (SUVN-502) (serotonin 6 receptor antagonist)	Suven Life Sciences Hyderabad, India	agitation in Alzheimer's disease	Phase III www.suven.com

Alzheimer's Disease

<u>Drug Name</u>	<u>Organization</u>	<u>Indication</u>	<u>Development Phase</u>
MEDI1814 (anti-amyloid beta mAb)	AstraZeneca Wilmington, DE	Alzheimer's disease	Phase I www.astrazeneca.com
mesenchymal stem cell therapy (allogeneic bone marrow-derived)	Longeveron Miami, FL	Alzheimer's disease	Phase I www.longeveron.com
MK-1942	Merck Kenilworth, NJ	Alzheimer's disease	Phase I completed www.merck.com
MK-8189	Merck Kenilworth, NJ	Alzheimer's disease	Phase I www.merck.com
MW150 (p38MAPK inhibitor)	NeuroKine Therapeutics New York, NY	Alzheimer's disease	Phase I completed www.neurokinetp.com
NA-831 (traneurocin) (neurogenesis stimulant)	NeuroActiva San Jose, CA	Alzheimer's disease	Phase II completed www.neuroactiva.com
NE3107 (ERK inhibitor)	BioVie Santa Monica, CA	Alzheimer's disease	Phase III www.bioviepharma.com
neflamapimod (VX-745) (p-38 mitogen-activated protein kinase inhibitor)	EIP Pharma Boston, MA	Alzheimer's disease	Phase II completed www.eippharma.com

Alzheimer's Disease

<u>Drug Name</u>	<u>Organization</u>	<u>Indication</u>	<u>Development Phase</u>
NNI-362 (neuron regenerative therapy)	NeuroNascent Clarksville, MD	Alzheimer's disease	Phase I www.neuronascent.com
NP001 (macrophage modulator)	Neuvivo Palo Alto, CA	Alzheimer's disease	Phase I www.neuvivo.com
NTRX-07 (cannabinoid receptor CB2 agonist)	NeuroTherapia Gates Mills, OH	Alzheimer's disease	Phase I www.neurotherapia.com
NLY01-AD (GLP1R agonist)	Neuraly Gaithersburg, MD	Alzheimer's disease	Phase II www.neuraly.com
pepinemab (anti-SEMA4D mAb)	Vaccinex Rochester, NY	Alzheimer's disease	Phase I/II www.vaccinex.com
PQ912 (varoglutamstat) (QC inhibitor)	Vivoryzon Therapeutics Halle, Germany	early Alzheimer's disease	Phase II www.vivoryzon.com
protollin (nasal vaccine)	I-Mab Biopharma Shanghai, China	Alzheimer's disease	Phase I www.i-mabbiopharma.com
PRX-005 (tau protein inhibitor)	Bristol-Myers Squibb Princeton, NJ Prothena Dublin, Ireland	Alzheimer's disease	Phase I www.bms.com

Alzheimer's Disease

<u>Drug Name</u>	<u>Organization</u>	<u>Indication</u>	<u>Development Phase</u>
PU-AD (icapamespib) (HSP90 inhibitor)	Samus Therapeutics Topsfield, MA	Alzheimer's disease	Phase II www.samustherapeutics.com
remternetug (LY3372993) (anti-N3pG-4 mAb)	Lilly Indianapolis, IN	Alzheimer's disease	Phase I www.lilly.com
Rexulti [®] brexpiprazole	Lundbeck Deerfield, IL Otsuka American Pharmaceutical Rockville, MD	agitation in Alzheimer's disease	Phase III www.lundbeck.com www.otsuka-us.com
RG6102 (brain shuttle gantenerumab)	Roche/Genentech South San Francisco, CA	Alzheimer's disease	Phase II www.roche.com
RG6289	Roche/Genentech South San Francisco, CA	Alzheimer's disease	Phase I www.roche.com
seltorexant (JNJ-7922) (orexin receptor type 2 antagonist)	Janssen Research & Development Raritan, NJ	probable Alzheimer's disease with clinically significant agitation/ aggression	Phase II www.janssen.com
semaglutide oral (GLP1 receptor agonist)	Novo Nordisk Plainsboro, NJ	Alzheimer's disease	Phase III www.novonordisk.com

Alzheimer's Disease

<u>Drug Name</u>	<u>Organization</u>	<u>Indication</u>	<u>Development Phase</u>
semorinemab (RG6100) (GLP-1 receptor agonist)	Roche/Genentech South San Francisco, CA	Alzheimer's disease	Phase II www.roche.com
simufilam (microfilament protein modulator)	Cassava Sciences Austin, TX	Alzheimer's disease	Phase III www.cassavasciences.com
SNK01 (autologous NK cell therapy)	NKGen Biotech Irvine, CA	Alzheimer's disease	Phase I www.nkgenbiotech.com
solanezumab (amyloid beta inhibitor)	Lilly Indianapolis, IN	preclinical Alzheimer's disease	Phase III www.lilly.com
T-817MA (edonergic) (amyloid beta-protein inhibitor)	FUJIFILM Toyama Chemical Tokyo, Japan	Alzheimer's disease	Phase II www.fujifilm.com
T3D-959 (PPAR-delta/gamma agonist)	T3D Therapeutics Research Triangle Park, NC	Alzheimer's disease	Phase II www.t3dtherapeutics.com
TB006 (anti-TIM3 mAb)	TrueBinding Foster City, CA	Alzheimer's disease	Phase I www.truebinding.com
TRx0237 (LMTX) (tau protein aggregation inhibitor/ TDP-43 aggregation inhibitor)	TauRx Pharmaceuticals Aberdeen, United Kingdom	Alzheimer's disease	Phase III www.taurx.com

Alzheimer's Disease

<u>Drug Name</u>	<u>Organization</u>	<u>Indication</u>	<u>Development Phase</u>
UB-311 (anti-amyloid endobody vaccine)	Vaxxinity Dallas, TX	Alzheimer's disease	Phase II www.vaxxinity.com
UE-2343 (11 β -HSD1 inhibitor)	Actinogen Medical Sydney, Australia	dementia in Alzheimer's disease	Phase II www.actinogen.com
VAC20101 (ACI-35.030) (anti-pTau vaccine)	AC Immune Lausanne, Switzerland Janssen Research & Development Raritan, NJ	Alzheimer's dementia	Phase I www.janssen.com
vafidemstat (ORY-2001) (LSD1/MAOB inhibitor)	Oryzon Genomics Boston, MA	Alzheimer's disease	Phase II completed www.oryzon.com
XPRO1595 (pegipanermin) (TNF-alpha inhibitor)	INmune Bio Boca Raton, FL	mild Alzheimer's disease	Phase II www.inmunebio.com

Arthritis

<u>Drug Name</u>	<u>Organization</u>	<u>Indication</u>	<u>Development Phase</u>
ABBV-154 (anti-TNF GRM ADC)	AbbVie North Chicago, IL	rheumatoid arthritis	Phase II www.abbvie.com

Arthritis

Drug Name

Organization

Indication

Development Phase

ABP 654
(ustekinumab biosimilar)

Amgen
Thousand Oaks, CA

psoriatic arthritis

Phase III
www.amgen.com

ALLN-346
(urate oxidase replacement)

Allena Pharmaceuticals
Newton, MA

gout

Phase II
www.allenapharma.com

ALN-XDH
(RNA interference)

Alnylam Pharmaceuticals
Cambridge, MA

gout

Phase I/II
www.alnylam.com

ampion
(cytokine modulator)

Ampio Pharmaceuticals
Englewood, CO

osteoarthritis of the knee

Phase III
www.ampiopharma.com

osteoarthritis of the hand

Phase II
www.ampiopharma.com

AMT-101
(IL-10 replacement)

Applied Molecular Transport
South San Francisco, CA

rheumatoid arthritis

Phase II
www.appliedmt.com

AR882
(SLC22A12 protein inhibitor)

Arthrosi Therapeutics
San Diego, CA

gout

Phase II
www.arthrosi.com

ATI-450 (zunsemetinib)
(MK2 inhibitor)

Aclaris Therapeutics
Wayne, PA

psoriatic arthritis,
rheumatoid arthritis

Phase II
www.aclaristx.com

Arthritis

<u>Drug Name</u>	<u>Organization</u>	<u>Indication</u>	<u>Development Phase</u>
AVT02 (adalimumab biosimilar)	Alvotech Reykjavik, Iceland	juvenile idiopathic arthritis, psoriatic arthritis, rheumatoid arthritis	application submitted www.alvotech.com
BIIB800 (tocilizumab biosimilar)	Biogen Cambridge, MA	juvenile rheumatoid arthritis, rheumatoid arthritis	Phase III www.biogen.com
bimekizumab (IL-17A/F protein inhibitor)	UCB Smyrna, GA	psoriatic arthritis	Phase III www.ucb.com
branebrutinib (agammaglobulinaemia tyrosine kinase inhibitor)	Bristol-Myers Squibb Princeton, NJ	rheumatoid arthritis	Phase II www.bms.com
BX-U001 (mesenchymal stem cell therapy)	Baylx Irvine, CA	rheumatoid arthritis	Phase I www.baylxinc.com
cevidoplenib (Syk kinase inhibitor)	Genosco Billerica, MA	rheumatoid arthritis	Phase II www.genosco.com
Cingal [®] hyaluronic acid	Anika Therapeutics Bedford, MA	osteoarthritis of the knee (+triamcinolone hexacetonide)	Phase III www.anika.com
Cosentyx [®] secukinumab	Novartis East Hanover, NJ	psoriatic arthritis (IV formulation)	Phase III www.novartis

Arthritis

Drug Name

Organization

Indication

Development Phase

dazodalibep
(CD40 ligand inhibitor)

Horizon Therapeutics
Deerfield, IL

rheumatoid arthritis

Phase II
www.horizontherapeutics.com

Dekavil
(IL-10 replacement)

Pfizer
New York, NY
Philogen
Siena, Italy

rheumatoid arthritis

Phase II
www.pfizer.com

deucravacitinib
(TYK2 kinase inhibitor)

Bristol-Myers Squibb
Princeton, NJ

psoriatic arthritis

Phase III
www.bms.com

dHACM
(cell replacement therapy)

MiMedx Group
Marietta, GA

osteoarthritis of the knee

Phase II
www.mimedx.com

dotinurad
(URAT1 inhibitor)

UR-1 Therapeutics
Miami, FL

gout

Phase I
www.fortressbiotech.com

DRL-RI
(rituximab biosimilar)

Dr Reddys Laboratories
Hyderabad, India

rheumatoid arthritis

Phase III
www.drreddys.com

DFV890
(NLRP3 inhibitor)

Novartis Pharmaceuticals
East Hanover, NJ

osteoarthritis

Phase II
www.novartis.com

DYV702
(pH modulation)

Dyve Biosciences
Camarillo, CA

gout

Phase II completed
www.dyvebio.com

Arthritis

<u>Drug Name</u>	<u>Organization</u>	<u>Indication</u>	<u>Development Phase</u>
EQ121 (JAK-1 inhibitor)	EQRx Cambridge, MA	rheumatoid arthritis	Phase II www.eqr.com
FX201 (humantakinogene hadenovec) (gene therapy)	Pacira Biosciences Tampa, FL	osteoarthritis of the knee	Phase I www.pacira.com
GNSC-001 (AAV-based gene therapy)	Genascence Palo Alto, CA	osteoarthritis	Phase I www.genascence.com
GS-5718 (IRAK4 inhibitor)	Gilead Sciences Foster City, CA	rheumatoid arthritis	Phase I www.gilead.com
GSK3858279 (anti-CCL17)	GlaxoSmithKline Research Triangle Park, NC	osteoarthritis pain	Phase I www.gsk.com
HB-adMSCs (autologous adipose derived mesenchymal stem cells)	Hope Biosciences Sugar Land, TX	rheumatoid arthritis	Phase I/II completed www.hope.bio
HP-5000 (diclofenac transdermal patch)	Noven Pharmaceuticals Tokyo, Japan	osteoarthritis of the knee	Phase III www.noven.com
IA-14069 (TNF-alpha inhibitor)	iLab Seoul, South Korea	rheumatoid arthritis	Phase I www.ilab.co.kr

Arthritis

<u>Drug Name</u>	<u>Organization</u>	<u>Indication</u>	<u>Development Phase</u>
IMC-2013 (cell replacement therapy)	ImmuneCyte Irvine, CA	osteoarthritis	Phase I www.immunecyte.com
IRL201805 (immunomodulator)	Revolobio Biotherapeutics New Orleans, LA	rheumatoid arthritis	Phase II www.revolobio.com
JNJ-4703 (immunomodulator)	Janssen Research & Development Raritan, NJ	rheumatoid arthritis	Phase I www.janssen.com
JNJ-4804 (immunomodulator)	Janssen Research & Development Raritan, NJ	psoriatic arthritis (combination therapy)	Phase II www.janssen.com
JointStem mesenchymal stem cell therapy	Nature cell Seoul, South Korea	osteoarthritis of the knee	Phase II/III www.naturecell.co.kr
JTE-051 (IL-2 inducible T cell kinase inhibitor)	Japan Tobacco/Akros Pharma Princeton, NJ	rheumatoid arthritis	Phase II completed www.akrospharma.com
Kevzara [®] sarilumab	Regeneron Tarrytown, NY Sanofi Bridgewater, NJ	polyarticular-course juvenile idiopathic arthritis, systemic juvenile idiopathic arthritis	Phase II www.regeneron.com www.sanofi.com
KPL-404 (CD40 antigen inhibitor)	Kiniksa Pharmaceuticals Lexington, MA	rheumatoid arthritis	Phase II www.kiniksa.com

Arthritis

Drug Name

Organization

Indication

Development Phase

LABP-104
(LANCL2 protein agonist)

Landos Biopharma
Blacksburg, VA

rheumatoid arthritis

Phase I
www.landosbiopharma.com

LC350189
(xanthine oxidase inhibitor)

LG Chem
Cambridge, MA

gout

Phase II completed
www.innovation.lgchem.com

LNA043
(ANGPTL3 agonist)

Novartis Pharmaceuticals
East Hanover, NJ

osteoarthritis (Fast Track)
(combination therapy),
osteoarthritis of the knee

Phase II
www.novartis.com

lorezivint
(CLK/DYRK inhibitor)

Biosplice Therapeutics
San Diego, CA

osteoarthritis of the knee

Phase III
www.biosplice.com

LRX712

Novartis Pharmaceuticals
East Hanover, NJ

osteoarthritis

Phase II
www.novartis.com

MEDI0618
(PAR2 antagonist)

AstraZeneca
Wilmington, DE

osteoarthritis

Phase I
www.astrazeneca.com

MEDI7352
(NGF x TNF bispecific antibody)

AstraZeneca
Wilmington, DE

osteoarthritis

Phase II
www.astrazeneca.com

Natrunix-SQ
(IL-1a inhibitor)

XBiotech
Austin, TX

arthritis

Phase I
www.vbiotech.com

Arthritis

<u>Drug Name</u>	<u>Organization</u>	<u>Indication</u>	<u>Development Phase</u>
NDI-034858 (TYK2 kinase inhibitor)	Nimbus Therapeutics Cambridge, MA	psoriatic arthritis	Phase II www.nimbustx.com
nipocalimab (Fc receptor antagonist)	Janssen Research & Development Raritan, NJ	rheumatoid arthritis	Phase II www.janssen.com
Olumiant® baricitinib	Lilly Indianapolis, IN	juvenile idiopathic arthritis	Phase III www.lilly.com
ORTD-1 (orynotide)	Oryn Therapeutics Vacaville, CA	rheumatoid arthritis	Phase I www.oryntherapeutics.com
Orencia® abatacept	Bristol-Myers Squibb Princeton, NJ	early seropositive rheumatoid arthritis	Phase III www.bms.com
OTEZLA® apremilast	Amgen Thousand Oaks, CA	juvenile psoriatic arthritis	Phase III www.amgen.com
otilimab (GSK3196165) (GMC-SF inhibitor)	GlaxoSmithKline Research Triangle Park, NC	rheumatoid arthritis	Phase III www.gsk.com
peresolimab (LY3462817) (PD-1 antibody agonist)	Lilly Indianapolis, IN	rheumatoid arthritis	Phase II www.lilly.com

Arthritis

<u>Drug Name</u>	<u>Organization</u>	<u>Indication</u>	<u>Development Phase</u>
PTP-001 (allogeneic cell therapy)	Bioventus Durham, NC	osteoarthritis	Phase I www.bioventus.com
ritlecitinib (JAK3/TEC inhibitor)	Pfizer New York, NY	rheumatoid arthritis (+/- zilmovisertib) (+tofacitinib)	Phase II www.pfizer.com
S-120083 (V120083)	Purdue Pharma Stamford, CT Shionogi Florham Park, NJ	osteoarthritis of the knee	Phase II completed www.shionogi.com
SAP-001 (urate transporter inhibitor)	Shanton Pharma Shanghai, China	gout	Phase II completed www.shantonpharma.com
SEL-212 (pegadricase) (urate oxidase replacement)	Selecta Biosciences Watertown, MA	chronic refractory gout	Phase III www.selectabio.com
SI-613 (diclofenac etalhyaluronate)	Seikagaku Tokyo, Japan	osteoarthritis of the knee	Phase II www.seikagaku.co.jp
Taltz [®] ixekizumab	Lilly Indianapolis, IN	juvenile idiopathic arthritis	Phase III www.lilly.com
tildrakizumab (anti-p19 subunit of IL-23 mAb)	Sun Pharmaceutical Mumbai, India	psoriatic arthritis	Phase III www.sunpharma.com

Arthritis

Drug Name

Organization

Indication

Development Phase

TLC599
(glucocorticoid receptor agonist)

Taiwan Liposome Company
Taipei, Taiwan

osteoarthritis of the knee

Phase III completed
www.tlcbio.com

tonogenchoncel-L
(allogeneic off-the-shelf cell therapy)

Kolon TissueGene
Rockville, MD

osteoarthritis of the knee

Phase III
www.tissuegene.com

osteoarthritis of the hip

Phase II
www.tissuegene.com

Tremfya®
guselkumab

Janssen Research & Development
Raritan, NJ

psoriatic arthritis structural
damage

Phase III
www.janssen.com

X0002
(cyclooxygenase inhibitor)

Techfields Pharma
Princeton, NJ

osteoarthritis of the knee

Phase III

Zofin
(nanoparticle-based therapeutic)

Organicell
Miami, FL

osteoarthritis of the knee

Phase I/II
www.organicell.com

zunsemetinib
(MK2 inhibitor)

Aclaris Therapeutics
Wayne, PA

psoriatic arthritis,
rheumatoid arthritis

Phase II
www.aclaristx.com

Cancer

<u>Drug Name</u>	<u>Organization</u>	<u>Indication</u>	<u>Development Phase</u>
64Cu-SAR-bisPSMA (SAR-bisPSMA)	Clarity Pharmaceuticals Sydney, Australia	castration-resistant prostate cancer	Phase I/II www.claritypharmaceuticals.com
67Cu-SAR-bisPSMA (SAR-bisPSMA)	Clarity Pharmaceuticals Sydney, Australia	castration-resistant prostate cancer	Phase I/II www.claritypharmaceuticals.com
1095 (PSMA-targeted iodine-131)	Lantheus N. Billerica, MA	metastatic castration resistant prostate cancer	Phase II www.lantheus.com
A166 (antibody drug conjugate)	Klus Pharma Princeton, NJ	breast cancer	Phase I/II www.kluspharma.com
A264 (SK264) (antibody drug conjugate)	Klus Pharma Princeton, NJ	breast cancer, ovarian cancer	Phase I/II www.kluspharma.com
AAA817 (Ac-PSMA-617) (radioligand therapy target PSMA)	Novartis Pharmaceuticals East Hanover, NJ	metastatic hormone-sensitive prostate cancer	Phase I www.novartis.com
abexinostat (HDAC inhibitor)	Xynomic Pharmaceuticals Poway, CA	follicular lymphoma (Fast Track)	Phase II www.xynomicpharma.com
AC0176 (AR degrader)	Accutar Biotechnology New York, NY	prostate cancer (Fast Track)	Phase I www.accutarbio.com

Cancer

<u>Drug Name</u>	<u>Organization</u>	<u>Indication</u>	<u>Development Phase</u>
AC0682 (ER degrader)	Accutar Biotechnology New York, NY	ER+ breast cancer	Phase I www.accutarbio.com
acapatamab (anti-PSMA x anti-CD3 bispecific T-cell engager)	Amgen Thousand Oaks, CA	prostate cancer	Phase I www.amgen.com
ACE1702 (ACC-oNK cell therapy)	Acepodia Alameda, CA	HER2+ metastatic breast cancer	Phase I www.acepodia.com
ACR-368 (prexasertib) (CHK1/CHK2 inhibitor)	Acrivon Therapeutics Watertown, MA	platinum resistant ovarian cancer	Phase II www.acrivon.com
adagloxad simolenin (cancer vaccine)	OBI Pharma Taipei City, Taiwan	triple negative breast cancer	Phase III www.obipharma.com
Adcetris® brentuximab vedotin	Seagen Bothell, WA	diffuse large B-cell lymphoma (DLBCL)	Phase III www.seagen.com
		Hodgkin lymphoma, peripheral T-cell lymphoma (PTCL), Hodgkin lymphoma (pediatric)	Phase II www.seagen.com
ADG106 (anti-CD137 mAb)	Adagene San Diego, CA	non-Hodgkin lymphoma	Phase I www.adagene.com

Cancer

<u>Drug Name</u>	<u>Organization</u>	<u>Indication</u>	<u>Development Phase</u>
ADX5-PSA (cancer vaccine)	Advaxis Princeton, NJ	metastatic castration-resistant prostate cancer (+pembrolizumab)	Phase II www.advaxis.com
AE37 (peptide cancer vaccine)	NuGenerex Immuno-Oncology Miramar, FL	triple negative breast cancer	Phase II www.nugenerexio.com
afuresertib (proto oncogene protein c-akt inhibitor)	Laekna Therapeutics Shanghai, China	platinum-resistant ovarian cancer	Phase II www.laekna.com
		HR+/HER2- breast cancer, metastatic castration-resistant prostate cancer	Phase I www.laekna.com
aglatimagene besadenovec (oncolytic viral immunotherapy)	Candel Therapeutics Needham, MA	localized intermediate/high risk prostate cancer (Fast Track)	Phase III www.candeltx.com
Aliqopa [®] copanlisib	Bayer Pharmaceuticals Whippany, NJ	non-Hodgkin lymphoma	Phase III www.bayer.com
ALRN-6924 (MDM2/MDMX dual inhibitor)	Aileron Therapeutics Boston, MA	p53-mutated breast cancer	Phase I www.aileronrx.com
amcenestrant (SERD)	Sanofi Bridgewater, NJ	adjuvant breast cancer, 1L metastatic breast cancer (+palbociclib)	Phase III www.sanofi.com

Cancer

<u>Drug Name</u>	<u>Organization</u>	<u>Indication</u>	<u>Development Phase</u>
AMG 176 (MCL-1 inhibitor)	Amgen Thousand Oaks, CA	chronic myelomonocytic leukemia	Phase I www.amgen.com
AMG 340 (anti-PSMA x anti-CD3 lower T cell affinity bispecific T-cell engager)	Amgen Thousand Oaks, CA	prostate cancer	Phase I www.amgen.com
AMG 404 (PD-1 mAb)	Amgen Thousand Oaks, CA	metastatic castration resistant prostate cancer	Phase I www.amgen.com
AMG 509 (STEAP1 XmAb antibody)	Amgen Thousand Oaks, CA	prostate cancer (Fast Track)	Phase I www.amgen.com
APG-2575 (Iisafoclax) (proto-oncogene protein c-bcl-2 inhibitor) ORPHAN DRUG	Ascentage Pharma Rockville, MD	breast cancer, chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL)	Phase I www.ascentage.com
ARV-471 (ER-targeting PROTAC® protein degrader)	Arvinas New Haven, CT Pfizer New York, NY	ER+/HER2- metastatic breast cancer	Phase II www.arvinas.com www.pfizer.com
ARV-766 (androgen receptor degrader)	Arvinas New Haven, CT	prostate cancer	Phase I www.arvinas.com

Cancer

<u>Drug Name</u>	<u>Organization</u>	<u>Indication</u>	<u>Development Phase</u>
ARX788 (tubulin inhibitor)	Ambrx La Jolla, CA	HER2+ metastatic breast cancer (Fast Track)	Phase II www.ambrx.com
ASTX030 (azacitidine/cedazuridine)	Astex Pharmaceuticals Pleasanton, CA	chronic myelocytic leukemia	Phase II/III www.astx.com
AZD5305 (PARP1 inhibitor)	AstraZeneca Wilmington, DE	metastatic prostate cancer (combination therapy)	Phase I/II www.astrazeneca.com
AZD7789 (PD1/TIM3 bispecific mAb)	AstraZeneca Wilmington, DE	Hodgkin lymphoma	Phase I/II www.astrazeneca.com
balixafortide (CXCR4 receptor antagonist)	Spexis Allschwil, Switzerland	breast cancer (Fast Track)	Phase III www.spexisbio.com
batiraxcept (GAS6-AXL pathway inhibitor)	Aravive Houston, TX	platinum resistant ovarian cancer (combination therapy) (Fast Track)	Phase III www.aravive.com
bavdegalutamide (androgen receptor degrader)	Arvinas New Haven, CT	prostate cancer (Fast Track)	Phase II www.arvinas.com
BAY 1895344 (ATR inhibitor)	Bayer Pharmaceuticals Whippany, NJ	mantle cell lymphoma, non-Hodgkin lymphoma, ovarian cancer	Phase I www.bayer.com

Cancer

Drug Name

Organization

Indication

Development Phase

Betalutin
177Lu-lilotomab satetraxetan
ORPHAN DRUG

Nordic Nanovector
Oslo, Norway

follicular lymphoma (Fast Track),
non-Hodgkin lymphoma

Phase I/II
www.nordicnanovector.com

BGB-11417
(Bcl-2 inhibitor)

BeiGene
Cambridge, MA

B-cell malignancies

Phase I
www.beigene.us

BGB-16673
(BTK degrader)

BeiGene
Cambridge, MA

B-cell malignancies

Phase I
www.beigene.us

bicalutamide implant
(androgen receptor antagonist)

Alessa Therapeutics
San Carlos, CA

prostate cancer

Phase I
www.alessatherapeutics.com

BMS-986218
(anti-CTLA-4 NF)

Bristol-Myers Squibb
Princeton, NJ

metastatic castration resistant
prostate cancer

Phase II
www.bms.com

BMS-986403

Bristol-Myers Squibb
Princeton, NJ

CLL/SLL (+chemotherapy)

Phase I
www.bms.com

BMS-99282
(CELMoD)

Bristol-Myers Squibb
Princeton, NJ

CLL/SLL, non-Hodgkin lymphoma

Phase I
www.bms.com

BNT112
(mRNA cancer vaccine)

BioNTech
Mainz, Germany

prostate cancer

Phase I/II
www.biontech.com

Cancer

Drug Name

Organization

Indication

Development Phase

BP1002 (L-Bcl-2 antisense oligonucleotide)	Bio-Path Bellaire, TX	CLL/SLL, Hodgkin lymphoma, non-Hodgkin lymphoma	Phase I www.biopathholdings.com
breast cancer vaccine	Anixa Biosciences San Jose, CA	breast cancer	Phase I www.anixa.com
Breyanzi® lisocabtagene maraleucel	Bristol-Myers Squibb Princeton, NJ	3L+ CLL, 3L+ follicular lymphoma, 3L+ marginal zone lymphoma	Phase II www.bms.com
Bria-IMT™ breast cancer vaccine	BriaCell Therapeutics Philadelphia, PA	advanced breast cancer (combination therapy) (Fast Track)	Phase I/II www.briacell.com
Brukinsa® zanubrutinib ORPHAN DRUG	BeiGene Cambridge, MA	CLL/SLL (Breakthrough Therapy)	application submitted www.beigene.us
		1L mantle cell lymphoma	Phase III www.beigene.us
		B-cell malignancies	Phase II www.beigene.us
BXCL701 (DPP inhibitor)	BioXcel Therapeutics New Haven, CT	metastatic castration-resistant prostate cancer (+pembrolizumab)	Phase I/II www.bioxceltherapeutics.com

Cancer

Drug Name

Organization

Indication

Development Phase

Cabometyx®
cabozantinib

Exelixis
Alameda, CA

metastatic castration resistant
prostate cancer

Phase III
www.exelixis.com

breast cancer, ovarian cancer

Phase I
www.exelixis.com

Calquence®
acalabrutinib

AstraZeneca
Wilmington, DE

1L CLL, 1L DLBCL,
1L mantle cell lymphoma

Phase III
www.astrazeneca.com

camidanlumab tesirine
(antibody drug conjugate)

ADC Therapeutics
New Providence, NJ

Hodgkin lymphoma

Phase II
www.adctherapeutics.com

camizestrant
(SERD)

AstraZeneca
Wilmington, DE

1L HR+ HER2- ESR1m breast cancer,
1L HR+ HER2- breast cancer

Phase III
www.astrazeneca.com

ER+ breast cancer

Phase II
www.astrazeneca.com

CAP-100
(CCR7 receptor antagonist)

Catapult Therapeutics
Lelystad, The Netherlands

CLL

Phase I
www.catapult-therapeutics.com

Cancer

Drug Name

Organization

Indication

Development Phase

capivasertib
(proto oncogene protein c-akt
inhibitor)

AstraZeneca
Wilmington, DE

PTEN-deficient metastatic hormone
sensitive prostate cancer,
1L metastatic triple negative
breast cancer, 1L triplet in breast
cancer, 2L+ breast cancer, metastatic
castration resistant prostate cancer

Phase III
www.astrazeneca.com

CAR-T cell therapy

Anixa Biosciences
San Jose, CA

ovarian cancer

Phase I
www.anixa.com

CC-90011
(LSD1 inhibitor)

Bristol-Myers Squibb
Princeton, NJ

non-Hodgkin lymphoma,
prostate cancer

Phase I
www.bms.com

CC-94676 (AR-LDD)
(androgen receptor
degradation enhancer)

Bristol-Myers Squibb
Princeton, NJ

metastatic castration resistant
prostate cancer

Phase I
www.bms.com

CC-96673
(CELMoD)

Bristol-Myers Squibb
Princeton, NJ

non-Hodgkin lymphoma

Phase I
www.bms.com

CC-97540
(CAR-T cell therapy)

Bristol-Myers Squibb
Princeton, NJ

DLBCL

Phase I
www.bms.com

CC-99282
(CELMoD)

Bristol-Myers Squibb
Princeton, NJ

non-Hodgkin lymphoma

Phase I
www.bms.com

Cancer

<u>Drug Name</u>	<u>Organization</u>	<u>Indication</u>	<u>Development Phase</u>
CCW702 (CD3 x PSMA bispecific antibody)	Calibr La Jolla, CA	prostate cancer	Phase I www.scripps.edu/science-and-medicine/calibr/
CDX-527 (PDL-1/CD27)	Celldex Hampton, NJ	ovarian cancer	Phase I www.celldex.com
CFI-400945 (PLK4 inhibitor)	Treadwell Therapeutics New York, NY	CMML, breast cancer, prostate cancer	Phase I www.treadwelltx.com
CFI-402257 (TTK inhibitor)	Treadwell Therapeutics New York, NY	2L ER+ breast cancer	Phase I www.treadwelltx.com
CLBR001 + SW1019 (CAR-T cell therapy)	Calibr La Jolla, CA	B-cell malignancies (Fast Track)	Phase I www.scripps.edu/science-and-medicine/calibr/
CONV01- α (PSMA directed antibody)	Convergent Therapeutics Cambridge, MA	advanced prostate cancer	Phase I www.convergentrx.com
Copiktra® duvelisib ORPHAN DRUG	Secura Bio Summerlin, NV	peripheral T-cell lymphoma, chronic lymphocytic leukemia (intermittent dosing), follicular lymphoma, CLL/SLL (+venetoclax), CLL/SLL (intermittent dosing), indolent non-Hodgkin lymphoma	Phase II www.securabio.com

Cancer

Drug Name

Organization

Indication

Development Phase

Cosela®
trilaciclib

G1 Therapeutics
Research triangle Park, NC

1L triple negative breast cancer
(Fast Track)

Phase III
www.g1therapeutics.com

triple negative breast cancer

Phase II
www.g1therapeutics.com

CS1001
(anti-PD-L1 mAb)
ORPHAN DRUG

CStone Pharmaceuticals
Shanghai, China

T-cell lymphoma
(Breakthrough Therapy)

Phase II
www.cstonepharma.com

CX-2009 (praluzatamab)
(CD166-directed probody
drug conjugate)

CytomX Therapeutics
South San Francisco, CA

HR+ HER2- non-amp breast
cancer

Phase II
www.cytomx.com

D-0502
(SERD)

InventisBio
Shanghai, China

breast cancer

Phase I

DAN-222
(DNA topoisomerase I inhibitor)

Dantari
Thousand Oaks, CA

breast cancer

Phase I
www.dantari.com

datopotamab deruxtecan
(DNA topoisomerase I inhibitor)

AstraZeneca
Wilmington, DE
Daiichi Sankyo
Basking Ridge, NJ

2-3L HR+ HER2- breast cancer,
1L triple negative breast cancer

Phase III
www.astrazeneca.com

triple negative breast cancer,
HR+ breast cancer

Phase I
www.astrazeneca.com

Cancer

<u>Drug Name</u>	<u>Organization</u>	<u>Indication</u>	<u>Development Phase</u>
DCVax[®]-L (cancer vaccine)	Northwest Biotherapeutics Bethesda, MD	metastatic ovarian cancer	Phase I www.nwbio.com
DCVax[®]-Prostate (cancer vaccine)	Northwest Biotherapeutics Bethesda, MD	prostate cancer	Phase II completed www.nwbio.com
DeTIL-0255 (cell therapy)	Nurix San Francisco, CA	ovarian cancer	Phase I www.nurixtrx.com
DKN-01 (sirexatamab) (DKK1 inhibitor)	Leap Therapeutics Cambridge, MA	prostate cancer	Phase I/II www.leaptx.com
DPV-001 (cancer vaccine)	UbiVac Portland, OR	breast cancer	Phase I www.ubivac.com
DS-6000 (CDH6-directed ADC)	Daiichi Sankyo Basking Ridge, NJ	ovarian cancer	Phase I www.daiichisankyo.com
DST-2970 (9CYP17A1 protein inhibitor)	DisperSol Technologies Georgetown, TX	prostate cancer	Phase I www.dispersoltech.com
DTRM-555 (BTK inhibitor)	DTRM Biopharma Zhejiang, China	CLL, non-Hodgkin lymphoma	Phase II

Cancer

Drug Name

Organization

Indication

Development Phase

DZD1516
(ERBB 2 receptor antagonist)

Dizal Pharmaceutical
Shanghai, China

breast cancer

Phase I
www.dizalpharma.com

EG12014
(trastuzumab biosimilar)

EirGenix
Taipei, Taiwan
Sandoz
Princeton, NJ

HER2+ breast cancer

application submitted
www.sandoz.com

eganelisib
(PI3K inhibitor)

Infinity Pharmaceuticals
Cambridge, MA

triple negative breast cancer
(Fast Track)

Phase II
www.infi.com

elacestrant (RAD1901)
(SERD)

Radius Health
Boston, MA

ER+ breast cancer (Fast Track)

application submitted
www.radiuspharm.com

Eligard®
leuprolide acetate

Tolmar Pharmaceuticals
Fort Collins, CO

HR+ breast cancer,
HR+ HER2- breast cancer

Phase III
www.tolmar.com

encequidar + oral paclitaxel

Athenex
Buffalo, NY

breast cancer (neoadjuvant)
(+dostarlimab)

Phase II
www.athenex.com

endoxifen
(SERM)

Atossa Therapeutics
Seattle, WA

breast cancer

Phase II
www.atossatherapeutics.com

Cancer

Drug Name

Organization

Indication

Development Phase

Enhertu®
trastuzumab deruxtecan

AstraZeneca
Wilmington, DE
Daiichi Sankyo
Basking Ridge, NJ

2L HER2+ breast cancer,
HER2 low breast cancer
(post-chemo)

application submitted
www.astrazeneca.com
www.daiichisankyo.com

3L HER2+ breast cancer,
HER2 low breast cancer (chemo naïve),
HER2+ breast cancer (post-
neoadjuvant), 1L HER2+ breast cancer,
HER2+ breast cancer (neoadjuvant)

Phase III
www.astrazeneca.com
www.daiichisankyo.com

triple negative breast cancer
(+durvalumab)

Phase II
www.astrazeneca.com
www.daiichisankyo.com

2L~/1L HER2+ breast cancer,
HER2 low breast cancer (post-chemo
& chemo naïve), breast cancer
(combination therapy)

Phase I
www.astrazeneca.com
www.daiichisankyo.com

enobosarm
(selective androgen receptor agonist)

Veru
Miami, FL

AR+ ER+ HER2- breast cancer
(Fast Track)

Phase III
www.verupharma.com

AR+ ER+ HER2- breast cancer
(+abemaciclib), triple negative
breast cancer (+sabizabulin)

Phase II
www.verupharma.com

Cancer

<u>Drug Name</u>	<u>Organization</u>	<u>Indication</u>	<u>Development Phase</u>
ENV-105 (antibody targeting endoglin)	Kairos Pharma Los Angeles, CA	prostate cancer	Phase I/II www.kairospharma.com
EP0057 (nanoparticle drug conjugate)	Ellipses Pharma London, United Kingdom	ovarian cancer	Phase II www.ellipses.life
epcoritamab (DuoBody CD3xCD20) ORPHAN DRUG	AbbVie North Chicago, IL Genmab Plainsboro, NJ	DLBCL	Phase III www.abbvie.com
		B-cell non-Hodgkin lymphoma, follicular lymphoma	Phase II www.abbvie.com
		CLL, indolent non-Hodgkin lymphoma (pediatric)	Phase I www.abbvie.com
EPI-7386 (androgen receptor antagonist)	ESSA Pharma Houston, TX	prostate cancer (Fast Track)	Phase I/II www.essapharma.com
Erleada [®] apalutamide	Janssen Research & Development Raritan, NJ	high risk prostate cancer, localized prostate cancer	Phase III www.janssen.com
etrumadenant (adenosine A2A/A2B antagonist)	Arcus Biosciences Hayward, CA Gilead Sciences Foster City, CA	metastatic castration resistant prostate cancer (combination therapy)	Phase II www.arcusbio.com

Cancer

<u>Drug Name</u>	<u>Organization</u>	<u>Indication</u>	<u>Development Phase</u>
evexomostat (MetAP2 inhibitor)	SynDevRx Cambridge, MA	triple negative breast cancer with baseline insulin resistance	Phase II www.syndevrx.com
evorpaupt (CD47 antigen inhibitor)	ALX Oncology South San Francisco, CA	breast cancer (combination therapy), non-Hodgkin lymphoma (combination therapy)	Phase I www.alxoncology.com
exicorilant (glucocorticoid receptor antagonist)	Corcept Therapeutics Menlo Park, CA	castration resistant prostate cancer (combination therapy)	Phase II www.corcept.com
fadracilib (CDK9/CDK2 inhibitor)	Cyclacel Pharmaceuticals Berkeley Heights, NJ	CLL	Phase I/II www.cyclacel.com
favezelimab (KM-4280) (IgG4 mAb)	Merck Whitehouse Station, NJ	non-Hodgkin lymphoma, Hodgkin lymphoma	Phase II www.merck.com
FOR46 (antibody drug conjugate)	Fortis Therapeutics San Diego, CA	metastatic castration resistant prostate cancer	Phase I www.fortistx.com
FR-alpha (anti-folate receptor alpha CAR-T cell therapy)	Tmunity Therapeutics Philadelphia, PA	ovarian cancer	Phase I www.tmunity.com
fruquintinib (VEGFR inhibitor)	Hutchison MediPharma Shanghai, China	breast cancer	Phase I www.hutch-med.com

Cancer

Drug Name

Organization

Indication

Development Phase

FT516
(CAR-NK cell therapy)

Fate Therapeutics
San Diego, CA

B-cell lymphoma

Phase I
www.fatetherapeutics.com

FT596
(CAR-NK cell therapy)

Fate Therapeutics
San Diego, CA

CLL, B-cell lymphoma

Phase I
www.fatetherapeutics.com

FT819
(CAR-T cell therapy)

Fate Therapeutics
San Diego, CA

CLL, B-cell lymphoma

Phase I
www.fatetherapeutics.com

FT-7051
(CBP/p300 inhibitor)

FORMA Therapeutics
Watertown, MA

metastatic castration resistant
prostate cancer

Phase I
www.formatherapeutics.com

fulvestrant
(SERD)

Eagle Pharmaceuticals
Woodcliff Lake, NJ

HR+ HER2- breast cancer

Phase I
www.eagleus.com

futibatinib (TAS-120)
(FGF/FGFR inhibitor)

Taiho Oncology
Princeton, NJ

breast cancer with FGFR 1/2
amplification

Phase II
www.taihooncology.com

fuzoloparib
(PARP inhibitor)

Hengrui Pharmaceuticals
Jiangsu, China

castration resistant prostate cancer

Phase III
www.hengrui.com

gavocabtagene autoleucel
(T-cell therapy)

TCR2 Therapeutics
Cambridge, MA

ovarian cancer

Phase I/II
www.tcr2.com

Cancer

<u>Drug Name</u>	<u>Organization</u>	<u>Indication</u>	<u>Development Phase</u>
gedatolisib (PI3K/mTOR inhibitor)	Celcuity Minneapolis, MN	metastatic breast cancer (Breakthrough Therapy)	Phase III www.celcuity.com
GEN-1 (IL-12 DNA plasmid vector) ORPHAN DRUG	Celsion Lawrenceville, NJ	ovarian cancer (Fast Track)	Phase II www.celsion.com
GEN-3009 (DuoHexaBody-CD37)	AbbVie North Chicago, IL	B-cell malignancies	Phase I www.abbvie.com
giredestrant (SERD)	Roche/Genentech South San Francisco, CA	1L ER+ HER2- metastatic breast cancer, adjuvant ER+ breast cancer, 1L ER+ HER2+ breast cancer (combination therapy)	Phase III www.roche.com
glofitamab (bispecific monoclonal antibody)	Roche/Genentech South San Francisco, CA	3L+ DLBCL, 2L+ DLBCL	Phase III www.roche.com
		1L ctDNA high-risk DLBCL	Phase II www.roche.com
GRN-300 (SIK2/SIK3 inhibitor)	Green3Bio Austin, TX	ovarian cancer	Phase I www.greenfirebio.com

Cancer

<u>Drug Name</u>	<u>Organization</u>	<u>Indication</u>	<u>Development Phase</u>
H3B-6545 (ER α inhibitor)	Eisai Woodcliff Lake, NJ	breast cancer	Phase I/II www.eisai.com
		breast cancer (+palbociclib)	Phase I www.eisai.com
HC-1119 (androgen receptor antagonist)	Hinova Pharmaceuticals Chengdu City, China	prostate cancer	Phase III www.hinovapharma.com
HC-5404 (EIF 2 kinase inhibitor)	HiberCell New York, NY	breast cancer (Fast Track)	Phase I www.hibercell.com
HH2853 (PRC2/EZH1/2 inhibitor)	Haihe Biopharma Shanghai, China	non-Hodgkin lymphoma	Phase I/II www.haihepharma.com
HMPL-760 (BTK inhibitor)	Hutchison MediPharma Shanghai, China	CLL/SLL, non-Hodgkin lymphoma	Phase I www.hutch-med.com
HPN536 (T lymphocyte stimulant)	Harpoon Therapeutics South San Francisco, CA	ovarian cancer	Phase I/II www.harpoontx.com
huMNC2-CAR44 (CAR-T cell therapy)	Minerva Biotechnologies Waltham, MA	breast cancer	Phase I/II www.minervabio.com

Cancer

Drug Name

Organization

Indication

Development Phase

iberdomide (CELMoD)	Bristol-Myers Squibb Princeton, NJ	non-Hodgkin lymphoma	Phase I www.bms.com
Ibrance [®] palbociclib	Pfizer New York, NY	ER+ HER2+ metastatic breast cancer	Phase III www.pfizer.com
		ER+ HER2- metastatic breast cancer (+ARV-471)	Phase II www.pfizer.com
IGM-2323 (imvotamab) (CD20 x CD3 bispecific antibody)	IGM Biosciences Mountain View, CA	CLL, non-Hodgkin lymphoma	Phase II www.igmbio.com
Imbruvica [®] ibrutinib	Janssen Research & Development Raritan, NJ Pharmacyclics (AbbVie) Sunnyvale, CA	1L CLL (+venetoclax; fixed duration), mantle cell lymphoma (combination therapy) (treatment naïve)	application submitted www.janssen.com
		mantle cell lymphoma (+venetoclax), indolent non- Hodgkin lymphoma	Phase III www.janssen.com
Imfinzi [®] durvalumab	AstraZeneca Wilmington, DE	1L metastatic triple negative breast cancer	Phase III www.astrazeneca.com

Cancer

<u>Drug Name</u>	<u>Organization</u>	<u>Indication</u>	<u>Development Phase</u>
IMGC936 (anti-ADAM9 ADC)	ImmunoGen Waltham, MA MacroGenics Rockville, MD	triple negative breast cancer	Phase I www.immunogen.com www.macrogenics.com
imlunestrant (SERD)	Lilly Indianapolis, IN	ER+ HER2- metastatic breast cancer	Phase III www.lilly.com
IN10018 (FAK/PTK2 protein inhibitor)	InxMed Nanjing, China	ovarian cancer (Fast Track)	Phase I/II www.en.inxmed.com
inavolisib (PI3K inhibitor)	Roche/Genentech South San Francisco, CA	1L HR+ metastatic breast cancer	Phase III www.roche.com
INKmune™ biologic delivery system	INmune Bio Boca Raton, FL	ovarian cancer	Phase I www.inmunebio.com
INO-5151 (DNA cancer vaccine)	Inovio Pharmaceuticals Plymouth Meeting, PA	prostate cancer	Phase I www.inovio.com
INT230-6 (cisplatin/vinblastine)	Intensity Therapeutics Westport, CT	breast cancer	Phase II www.intensitytherapeutics.com
IO-202 (LILRB4 inhibitor)	Immune-Onc Therapeutics Palo Alto, CA	CMML	Phase I www.immune-onc.com

Cancer

<u>Drug Name</u>	<u>Organization</u>	<u>Indication</u>	<u>Development Phase</u>
IONIS-AR-2.5Rx (androgen receptor antagonist)	Ionis Pharmaceuticals Carlsbad, CA	prostate cancer	Phase II www.ionispharma.com
IOV-2001 (adoptive cell therapy)	Iovance Biotherapeutics San Carlos, CA	CLL/SLL	Phase I www.iovance.com
ipatasertib (proto oncogene protein c-akt inhibitor)	Roche/Genentech South San Francisco, CA	1L castration resistant prostate cancer (combination therapy)	Phase III www.roche.com
IRX4204 (RXR agonist)	Io Therapeutics Spring, TX	HER2+ breast cancer, prostate cancer	Phase II www.io-therapeutics.com
Istodax [®] romidepsin	Bristol-Myers Squibb Princeton, NJ	peripheral T-cell lymphoma	Phase III www.bms.com
ITIL-306 (autologous genetically modified cell therapy)	Instill Bio Dallas, TX	ovarian cancer	Phase I www.instillbio.com
JBH492 (antibody drug conjugate)	Novartis Pharmaceuticals East Hanover, NJ	CLL	Phase I www.novartis.com

Cancer

<u>Drug Name</u>	<u>Organization</u>	<u>Indication</u>	<u>Development Phase</u>
JNJ-4681 (BTK inhibitor)	Janssen Research & Development Raritan, NJ	CLL, non-Hodgkin lymphoma	Phase I www.janssen.com
JNJ-6333 (MALT1 inhibitor)	Janssen Research & Development Raritan, NJ	CLL, non-Hodgkin lymphoma	Phase I www.janssen.com
JNJ-6420 (ionizing radiation emitter)	Janssen Research & Development Raritan, NJ	prostate cancer	Phase I www.janssen.com
JNJ-8343 (KLK2 x CD3 bispecific antibody)	Janssen Research & Development Raritan, NJ	prostate cancer	Phase I www.janssen.com
JNJ-8780 (CD3 x CD22 bispecific antibody)	Janssen Research & Development Raritan, NJ	CLL, non-Hodgkin lymphoma	Phase I www.janssen.com
JNJ-8902 (TMEFF2 inhibitor)	Janssen Research & Development Raritan, NJ	prostate cancer	Phase I www.janssen.com
JNJ-9414 (CAR-T cell therapy)	Janssen Research & Development Raritan, NJ	prostate cancer	Phase I www.janssen.com
Kadcyla [®] ado-trastuzumab emtansine	Roche/Genentech South San Francisco, CA	2L+ HER2+ PD-L1+ metastatic breast cancer, HER2+ early breast cancer (high risk) (combination therapy)	Phase III www.roche.com

Cancer

<u>Drug Name</u>	<u>Organization</u>	<u>Indication</u>	<u>Development Phase</u>
KITE-363 (CD19/20 bicistronic)	Kite Pharma (Gilead) Santa Monica, CA	3L+ DLBCL	Phase I www.gilead.com
KPG-121 (angiogenesis inhibitor)	Kangpu Biopharmaceuticals Shanghai, China	castration resistant prostate cancer	Phase I www.kangpugroup.com
Keytruda [®] pembrolizumab	Merck Kenilworth, NJ	ovarian cancer, prostate cancer	Phase III www.merck.com
Kisqali [®] ribociclib	Novartis Pharmaceuticals East Hanover, NJ	HR+, HER2- breast cancer (adjuvant)	Phase III www.novartis.com
KUR-502 (CAR-NKT cell therapy)	Athenex Buffalo, NY	r/r leukemia and lymphoma	Phase I www.athenex.com
ladiratuzumab vedotin (antibody-drug conjugate)	Merck Whitehouse Station, NJ Seagen Bothell, WA	1L metastatic triple-negative breast cancer (combination therapy), prostate cancer	Phase II www.seagen.com
		r/r metastatic breast cancer	Phase I www.seagen.com

Cancer

<u>Drug Name</u>	<u>Organization</u>	<u>Indication</u>	<u>Development Phase</u>
LAE001/prednisone (CYP11B2/CYP17 inhibitor)	Laekna Therapeutics Shanghai, China	metastatic castration resistant prostate cancer	Phase I/II www.laekna.com
lasofoxifene (oral SERM)	Sermonix Pharmaceuticals Columbus, OH	breast cancer (Fast Track)	Phase II www.sermonixpharma.com
LAVA-1207 (bispecific T-cell engager therapy)	Lava Therapeutics Philadelphia, PA	metastatic castration resistant prostate cancer	Phase I/II www.lavatherapeutics.com
Lenvima [®] lenvatinib	Eisai Ridgefield, NJ Merck Whitehouse Station, NJ	prostate cancer (+pembrolizumab)	Phase II www.merck.com
lenzilumab (anti-GM-CSF antibody)	Humanigen Short Hills, NJ	non-Hodgkin lymphoma (combination therapy)	Phase III www.humanigen.com
lerociclib (CDK4/6 inhibitor)	EQRx Cambridge, MA	advanced breast cancer	Phase II www.erqx.com
leronlimab (CCR5 antagonist)	CytoDyn Vancouver, WA	triple negative breast cancer (Fast Track)	Phase II www.cytodyn.com

Cancer

<u>Drug Name</u>	<u>Organization</u>	<u>Indication</u>	<u>Development Phase</u>
lorigerlimab (PD-1 × CTLA-4 bispecific antibody)	MacroGenics Rockville, MD	metastatic castration resistant prostate cancer	Phase II www.macrogenics.com
LOXO-338 (Bcl-2 inhibitor)	Lilly (LOXO Oncology) Indianapolis, IN	B-cell malignancies	Phase I www.lilly.com
LP-108 (Bcl-2 inhibitor)	Newave Pharmaceuticals Pleasanton, CA	CMML	Phase I
Lu-177-PSMA-I&T (ionizing radiation emitter)	Curium US St. Louis, MO	metastatic castration resistant prostate cancer	Phase III www.curiumpharma.com
Lunsumio [®] mosunetuzumab ORPHAN DRUG	Roche/Genentech South San Francisco, CA	3L+ follicular lymphoma (Breakthrough Therapy)	application submitted www.roche.com
		2L+ follicular lymphoma, 2L+ DLBCL	Phase III www.roche.com
		CLL, B-cell non-Hodgkin lymphoma	Phase I www.roche.com
luxepatinib (CG-806) (BTK/FLT3 inhibitor)	Aptose Biosciences San Diego, CA	CLL/SLL, non-Hodgkin lymphoma	Phase I www.aptose.com

Cancer

Drug Name

Organization

Indication

Development Phase

LY3849524 (LOXO-783)
(PI3K α inhibitor)

Lilly (LOXO Oncology)
Indianapolis, IN

breast cancer

Phase I
www.lilly.com

Lynparza®
olaparib

AstraZeneca
Wilmington, DE

1L ovarian cancer (combination
therapy), 1L BRCAwt ovarian
cancer, prostate cancer
(combination therapy)

Phase III
www.astrazeneca.com

magrolimab (GS-4721)
(CD47 inhibitor)

Gilead Sciences
Foster City, CA

triple negative breast cancer

Phase II
www.gilead.com

DLBCL (Fast Track)

Phase I/II
www.gilead.com

maveropepimut-S
(peptide cancer vaccine)
ORPHAN DRUG

IMV
Cambridge, MA

ovarian cancer (Fast Track),
advanced metastatic breast
cancer (+pembrolizumab),
DLBCL (+pembrolizumab)

Phase II
www.imv-inc.com

breast cancer (neoadjuvant)

Phase I
www.imv-inc.com

MB-106
(CAR-T cell therapy)

Mustang Bio
Worcester, MA

CLL, non-Hodgkin lymphoma

Phase I/II
www.mustangbio.com

Cancer

<u>Drug Name</u>	<u>Organization</u>	<u>Indication</u>	<u>Development Phase</u>
MBM-02 (free radical scavenger antioxidant)	Matrix Biomed Irvine, CA	prostate cancer	Phase II www.matrixbiomed.com
mecbotamab vedotin (BA3011) (AXL inhibitor)	BioAtla San Diego, CA	ovarian cancer	Phase II www.bioalta.com
MEN1611 (PI3K inhibitor)	Menarini Florence, Italy	breast cancer	Phase I www.menarini.com
MGC018 (anti-B7-H3 mAb)	MacroGenics Rockville, MD	metastatic castration resistant prostate cancer	Phase II www.macrogenics.com
mirdametinib (MEK Inhibitor)	Springworks Therapeutics Stamford, CT	ER+ metastatic breast cancer (+fulvestrant)	Phase I www.springworkstx.com
mirvetuximab soravtansine (anti-FRalpha ADC) ORPHAN DRUG	ImmunoGen Waltham, MA	FRa-high platinum resistant ovarian cancer (Fast Track)	application submitted www.immunogen.com
MK-7684A pembrolizumab + vibostolimab coformulation	Merck Kenilworth, NJ	breast cancer, prostate cancer	Phase II www.merck.com
ModraDoc006/r (oral docetaxel/ritonavir)	Modra Pharmaceuticals Amsterdam, Netherlands	castration resistant prostate cancer, metastatic prostate cancer	Phase II www.modrapharmaceuticals.com

Cancer

<u>Drug Name</u>	<u>Organization</u>	<u>Indication</u>	<u>Development Phase</u>
Monjuvi® tasfasitamab ORPHAN DRUG	Incyte Wilmington, DE Morphosys Boston, MA	1L DLBCL, follicular lymphoma, marginal zone lymphoma	Phase III www.incyte.com www.morphosys.com
MS-553 (PKC-beta inhibitor)	MingSight Pharmaceuticals San Diego, CA	CLL/SLL	Phase I/II www.mindsight.com
MVI-118 (pTVG-AR cancer vaccine)	Madison Vaccines Madison, WI	prostate cancer	Phase II www.madisonvaccines.com
MVI-816 (pTVG-HP cancer vaccine)	Madison Vaccines Madison, WI	prostate cancer	Phase II www.madisonvaccines.com
navicixizumab (anti-DLL4 x VEGF bispecific antibody)	OncXerna Therapeutics Waltham, MA	ovarian cancer (Fast Track)	Phase II www.oncxerna.com
NanoPac® paclitaxel nanoformulation ORPHAN DRUG	Nanology Fort Worth, TX	ovarian cancer, prostate cancer	Phase II www.nanology.us
navtemadlin (proto-oncogene protein c mdm2 inhibitor)	Kartos Therapeutics Redwood City, CA	CLL, chronic myeloid leukemia DLBCL	Phase I www.kartosthera.com

Cancer

Drug Name

Organization

Indication

Development Phase

NBE-002
(antibody drug conjugate)

NBE-Therapeutics
Basel, Switzerland

triple negative breast cancer

Phase I/II
www.nbe-therapeutics.com

nemvaleukin alfa
(interleukin-2 receptor agonist)

Alkermes
Waltham, MA

ovarian cancer (Fast Track)

Phase III
www.alkermes.com

Nerlynx[®]
neratinib

Puma Biotechnology
Los Angeles, CA

HER2+ metastatic breast cancer
with brain mets, HER2-mutant
breast cancer

Phase II
www.pumabiotechnology.com

nirogacestat
(gamma secretase inhibitor)

SpringWorks Therapeutics
Stamford, CT

ovarian granulosa cell tumors

Phase II
www.springworkstx.com

NKX019
(CAR-NK cell therapy)

Nkarta
South San Francisco, CA

CLL/SLL, non-Hodgkin lymphoma

Phase I
www.nkartatx.com

NT-17 (efineptakin alfa)
(long acting IL-17)

NeoImmuneTech
Rockville, MD

DLBCL, breast cancer,
ovarian cancer

Phase I
www.neoimmunetech.com

Nubeqa[®]
darolutamide

Bayer Pharmaceuticals
Whippany, NJ

prostate cancer (adjuvant)

Phase III
www.bayer.com

NX-2127
(BTK degrader)

Nurix
San Francisco, CA

CLL, non-Hodgkin lymphoma

Phase I
www.nurixtx.com

Cancer

<u>Drug Name</u>	<u>Organization</u>	<u>Indication</u>	<u>Development Phase</u>
NX-5948 (BTK degrader)	Nurix San Francisco, CA	CLL/SLL, non-Hodgkin lymphoma	Phase I www.nurixtx.com
odetiglucon (Imprime PGG) (adaptive immune modulator)	HiberCell New York, NY	HR+ HER2- metastatic breast cancer (+pembrolizumab)	Phase II www.hibercell.com
odronextamab (CD20 x CD3 mAb)	Regeneron Tarrytown, NY	B-cell non-Hodgkin lymphoma	Phase II www.regeneron.com
onapristone (ONA-XR) (progesterone receptor antagonist)	Context Therapeutics Philadelphia, PA	1L metastatic breast cancer, 2L/3L metastatic breast cancer	Phase II www.contexttherapeutics.com
onilcamotide (RV001V) (peptide cancer vaccine)	RhoVac Lund, Sweden	prostate cancer (Fast Track)	Phase II www.rhovac.com
onvansertib (PLK1 inhibitor)	Cardiff Oncology San Diego, CA	metastatic castration resistant prostate cancer	Phase II www.cardiffoncology.com
OP-1250 (ER antagonist/SERD)	Olema Pharmaceuticals San Francisco, CA	breast cancer (Fast Track)	Phase I/II www.olema.com

Cancer

Drug Name

Organization

Indication

Development Phase

Opdivo®
nivolumab

Bristol-Myers Squibb
Princeton, NJ

1L metastatic castration resistant
prostate cancer

Phase III
www.bms.com

ER+/HER2- breast cancer
(+CDK4/6 inhibitor) (neoadjuvant)

Phase II
www.bms.com

Opdivo® + Yervoy®
nivolumab + ipilimumab

Bristol-Myers Squibb
Princeton, NJ

2L metastatic castration resistant
prostate cancer

Phase II
www.bms.com

oregovomab
(BTK inhibitor)

OncoQuest
Edmonton, Canada

1L ovarian cancer

Phase III
www.oncoquestiinc.com

platinum resistant ovarian cancer

Phase II
www.oncoquestinc.com

ORIC-944
(PRC2 inhibitor)

ORIC Pharmaceuticals
South San Francisco, CA

prostate cancer

Phase I
www.oricpharma.com

ORIN1001
(ERN2 protein inhibitor)

Orinove
Newbury Park, CA

breast cancer (Fast Track)

Phase I/II
www.orinove.com

OTS167
(MELK inhibitor)

OncoTherapy Science
Kawasaki City, Japan

advanced breast cancer,
triple negative breast cancer

Phase I
www.oncotherapy.co.jp

Cancer

<u>Drug Name</u>	<u>Organization</u>	<u>Indication</u>	<u>Development Phase</u>
ozuriftamab vedotin (BA3021) (ROR2 inhibitor)	BioAlta San Diego, CA	ovarian cancer	Phase II www.bioalta.com
patritumab deruxtecan (HER3-DXd) (DNA topoisomerase I inhibitor)	Daiichi Sankyo Basking Ridge, NJ	HER3+ breast cancer	Phase I www.daiichi.com
pelareorep (immuno-oncolytic reovirus)	Oncolytics Biotech San Diego, CA	HR+ HER2- metastatic breast cancer, triple negative breast cancer (Fast Track)	Phase II www.oncolyticsbiotech.com
		early breast cancer	Phase I www.oncolyticsbiotech.com
PF-06821497 (EZH2 inhibitor)	Pfizer New York, NY	prostate cancer	Phase I www.pfizer.com
PF-06873600 (CDK4 inhibitor)	Pfizer New York, NY	metastatic breast cancer	Phase I www.pfizer.com
PF-07104091 (CDK2 inhibitor)	Pfizer New York, NY	metastatic breast cancer, metastatic breast cancer (+PF-07220060), metastatic breast cancer (+palbociclib)	Phase I www.pfizer.com

Cancer

<u>Drug Name</u>	<u>Organization</u>	<u>Indication</u>	<u>Development Phase</u>
PF-07220060 (CDK4 inhibitor)	Pfizer New York, NY	metastatic breast cancer	Phase I www.pfizer.com
PF-07248144 (KAT6A epigenetic modifier)	Pfizer New York, NY	metastatic breast cancer	Phase I www.pfizer.com
PF-07260437 (B7H4 x CD3 bispecific antibody)	Pfizer New York, NY	metastatic breast cancer	Phase I www.pfizer.com
PF-07901801 (TTI-622) (CD47 antigen inhibitor)	Pfizer New York, NY	DLBCL, ovarian cancer	Phase I www.pfizer.com
Phesgo [®] pertuzumab/trastuzumab/ hyaluronidase-zzxf	Roche/Genentech South San Francisco, CA	HER2+ breast cancer	Phase I www.roche.com
pidnarulex (G-quadruplex stabilizer)	Senhwa Biosciences San Diego, CA	breast cancer, metastatic castration resistant prostate cancer, ovarian cancer (Fast Track)	Phase I www.senhwabio.com
Piqray [®] alpelisib	Novartis Pharmaceuticals East Hanover, NJ	HER2+ advanced breast cancer, triple negative breast cancer, ovarian cancer	Phase III www.novartis.com

Cancer

<u>Drug Name</u>	<u>Organization</u>	<u>Indication</u>	<u>Development Phase</u>
pirtobrutinib (BTK inhibitor)	Lilly Indianapolis, IN	mantle cell lymphoma (prior BTK)	application submitted www.lilly.com
		1L CLL, mantle cell lymphoma (monotherapy)	Phase III www.lilly.com
		B-cell malignancies	Phase II www.lilly.c0om
plamotamab (CD20 x CD3 bispecific antibody)	Xencor Monrovia, CA	DLBCL	Phase II www.xencor.com
Pluvicto [®] lutetium Lu177 vipivotide tetraxetan	Novartis Pharmaceuticals East Hanover, NJ	metastatic hormone sensitive prostate cancer, metastatic castration resistant prostate cancer (pre-taxane)	Phase III www.novartis.com
PLX-2853 (BET inhibitor)	Daiichi Sankyo Basking Ridge, NJ	ovarian cancer, prostate cancer	Phase I www.daiichi.com
PMD-026 (RSK inhibitor)	Phoenix Molecular Designs Vancouver, Canada	breast cancer	Phase I www.phoenixmd.ca
PNT-2002 (ionising radiation emitter)	POINT Biopharma Indianapolis, IN	metastatic castration-resistant prostate cancer	Phase III www.pointbiopharma.com

Cancer

<u>Drug Name</u>	<u>Organization</u>	<u>Indication</u>	<u>Development Phase</u>
Polivy® polatuzumab vedotin-piiq	Roche/Genentech South San Francisco, CA	1L DLBCL	Phase III www.roche.com
P-PSMA-101 (CAR-T cell therapy)	Poseida Therapeutics San Diego, CA	prostate cancer	Phase I www.poseida.com
PRL-02 (abiraterone decanoate)	Propella Therapeutics Pittsboro, NC	prostate cancer	Phase I/II www.propellatx.com
Provenge® sipuleucel-T	Dendreon Seal Beach, CA	newly diagnosed prostate cancer	Phase III www.dendreon.com
prxelutamide (GT0918) (TMPRSS2 inhibitor)	Kintor Pharmaceuticals Suzhou, China	metastatic castration resistant prostate cancer	Phase II www.en.kintor.com.cn
PSB202 (T lymphocyte stimulant)	Sound Biologics Bothell, WA	CLL/SLL, non-Hodgkin lymphoma	Phase I www.soundbiologics.com
PT-112 (imifoplatin) (immunogenic)	Promontory Therapeutics New York, NY	metastatic castrate-resistant prostate cancer	Phase II www.promontorytx.com
racemetyrosine (SM-88) (dysfunctional tyrosine derivative)	Tyme Technologies Bedminster, NJ	HR+ HER2- breast cancer	Phase II www.tymeinc.com

Cancer

<u>Drug Name</u>	<u>Organization</u>	<u>Indication</u>	<u>Development Phase</u>
REGN4018 (ubamatamab) (MUC16 x CD3 bispecific antibody)	Regeneron Tarrytown, NY	platinum resistant ovarian cancer	Phase I www.regeneron.com
REGN4336 (PSMA x CD3 bispecific antibody)	Regeneron Tarrytown, NY	prostate cancer	Phase I www.regeneron.com
REGN5668 (MUC16 x CD28 bispecific antibody)	Regeneron Tarrytown, NY	recurrent ovarian cancer	Phase I www.regeneron.com
REGN 5678 (PSMA x CD28 bispecific antibody)	Regeneron Tarrytown, NY	prostate cancer	Phase I www.regeneron.com
relacorilant (glucocorticoid receptor antagonist)	Corcept Therapeutics Menlo Park, Ca	ovarian cancer (+Nab-paclitaxel)	Phase III www.corcept.com
		castration resistant prostate cancer (+enzalutamide)	Phase II www.corcept.com
RG6333 (CD19 x CD28 bispecific antibody)	Roche/Genentech South San Francisco, CA	non-Hodgkin lymphoma (+glofitamab)	Phase I www.roche.com
RGT-419B (CDK2/4/6 inhibitor)	Regor Pharmaceuticals Cambridge, MA	HR+ HER2- breast cancer	Phase I www.regor.com

Cancer

Drug Name

Organization

Indication

Development Phase

rintodestrant
(SERD)

G1 Therapeutics
Research Triangle Park, NC

breast cancer

Phase II completed
www.g1therapeutics.com

Rubraca[®]
rucaparib

Clovis Oncology
Boulder, CO

1L ovarian cancer (maintenance therapy), metastatic castration resistance prostate cancer with BRCA or ATM mutations (Breakthrough Therapy)

Phase III
www.clovisoncology.com

runimotamab (RG6194)
(HER2 x CD3 bispecific antibody)

Roche/Genentech
South San Francisco, CA

breast cancer

Phase I
www.roche.com

RVT-2001 (H3B-8800)
(SF3B1 modulator)
ORPHAN DRUG

Hemavert Sciences (Roviant)
Basel, Switzerland

CMML

Phase I
www.roviant.com

sabizabulin
(oral cytoskeleton disruptor)

Veru
Miami, FL

metastatic castration and androgen receptor prostate cancer

Phase III
www.verupharma.com

AR+ ER+ HER2- breast cancer

Phase II
www.verupharma.com

samuraciclib (CT7001)
(CDK7 inhibitor)

Carrick Therapeutics
Boston, MA

ER+ breast cancer (Fast Track)

Phase I/II
www.carricktherapeutics.com

Cancer

Drug Name

Organization

Indication

Development Phase

SAR444245
(non-alpha IL-2)

Sanofi
Bridgewater, NJ

B-cell malignancies (combination
therapy)

Phase II
www.sanofi.com

Scemblix®
asciminib

Novartis Pharmaceuticals
East Hanover, NJ

1L chronic myeloid leukemia

Phase III
www.novartis.com

2L chronic myeloid leukemia
(pediatric)

Phase II
www.novartis.com

SCO-088
(Bcr-Abl kinase inhibitor)

Sun Pharma Advanced Research
Mumbai, India

chronic myeloid leukemia

Phase I
www.sparc.life

SCO-120
(SERD)

Sun Pharma Advanced Research
Mumbai, India

breast cancer

Phase I
www.sparc.life

SL-172154
(recombinant fusion protein)

Shattuck Labs
Austin, TX

ovarian cancer

Phase I
www.shattuck;abs.com

SM-88
(D,L-alpha-metyrosine)

Tyme Technologies
Bedminster, NJ

HR+ HER2- breast cancer

Phase II
www.tymeinc.com

SRF-617
(anti-CD39 antibody)

Surface Oncology
Cambridge, MA

prostate cancer

Phase II
www.surfaceoncology.com

Cancer

<u>Drug Name</u>	<u>Organization</u>	<u>Indication</u>	<u>Development Phase</u>
STAR-LLD (lenalidomide)	Starton Therapeutics Paramus, NJ	CLL	Phase I www.startontx.com
stenoparib (2X-121) (PARP/tankyrase inhibitor)	Allarity Therapeutics Cambridge, MA	advanced ovarian cancer	Phase II www.allarity.com
STRO-001 (antibody drug conjugate)	Sutro Biopharma South San Francisco, CA	B-cell non-Hodgkin lymphoma (Fast Track)	Phase I www.sutrobio.com
STRO-002 (antibody drug conjugate)	Sutro Biopharma South San Francisco, CA	epithelial ovarian cancer (Fast Track)	Phase I www.sutrobio.com
TAK-007 (CAR NK-cell therapy)	Takeda Lexington, MA	non-Hodgkin lymphoma	Phase II www.takeda.com
TAK-940 (CAR-T cell therapy)	Takeda Lexington, MA	B-cell malignancies	Phase I www.takeda.com
Talzenna [®] talazoparib	Pfizer New York, NY	1L metastatic castration resistant prostate cancer (+enzalutamide), DDR-deficient metastatic castration sensitive prostate cancer (+enzalutamide)	Phase III www.pfizer.com

Cancer

<u>Drug Name</u>	<u>Organization</u>	<u>Indication</u>	<u>Development Phase</u>
tarlatamab (anti-DLL3 x anti-CD3 bispecific T-cell engager)	Amgen Thousand Oaks, CA	neuroendocrine prostate cancer	Phase I www.amgen.com
TAS3681 (androgen receptor antagonist/ down-regulator)	Taiho Oncology Princeton, NJ	prostate cancer	Phase I www.taihooncology.com
tavokinogene telseplasmid IL-12 gene therapy)	OncoSec Medical Pennington, NJ	triple negative breast cancer (+pembrolizumab)	Phase II www.oncosec.com
TAVT-45 (CYP17A1 inhibitor)	Tavanta Therapeutics King of Prussia, PA	prostate cancer	Phase III www.tavanta.com
Tazverik® tazemetostat	Epizyme Cambridge, MA	2L follicular lymphoma (combination therapy)	Phase III www.epizyme.com
		prostate cancer	Phase II www.epizyme.com
TC-510 (T cell therapy)	TCR2 Therapeutics Cambridge, MA	triple negative breast cancer, ovarian cancer	Phase I/II www.tcr2.com
TCR T-cell therapy	Alaunos Therapeutics Houston, TX	ovarian cancer	Phase I www.alaunos.com

Cancer

<u>Drug Name</u>	<u>Organization</u>	<u>Indication</u>	<u>Development Phase</u>
Tecartus® brexucabtagene autoleucl	Kite Pharma (Gilead) Santa Monica, CA	B-cell non-Hodgkin lymphoma (pediatric)	Phase I/II www.gilead.com
Tecentriq® atezolizumab	Roche/Genentech South San Francisco, CA	1L triple negative breast cancer, adjuvant triple negative breast cancer (adjuvant)	Phase III www.roche.com
tenalisib (dual PI3K inhibitor) ORPHAN DRUG	Rhizen Pharmaceuticals Basel, Switzerland	1L peripheral T-cell lymphoma (Fast Track)	Phase II www.rhizen.com
TG-1801 (CD47 x CD19 bispecific antibody)	TG Therapeutics Morrisville, NC	CLL/SLL, non-Hodgkin lymphoma	Phase I www.tgtherapeutics.com
TG4050 (cancer vaccine)	Transgene Boston, MA	ovarian cancer	Phase I www.transgene.fr
tislelizumab (anti-PD-1)	BeiGene Cambridge, MA	Hodgkin lymphoma	Phase II www.beigene.us
Tivdak® tisotumab vedotin-tftv	Seagen Bothell, WA	2L platinum resistant ovarian cancer	Phase II www.seagen.com

Cancer

Drug Name

Organization

Indication

Development Phase

TJ004309 (differentiated CD73 antibody)	I-MAB Biopharma Shanghai, China	ovarian cancer	Phase II www.i-mabbiopharma.com
TLPO (tumor lysate particle only vaccine)	Elios Therapeutics Austin, TX	ovarian cancer (adjuvant)	Phase II www.eliotherapeutics.com
TmPSMA (PSMA CAR-T cell therapy)	Tmunity Philadelphia, PA	prostate cancer	Phase I www.tmunity.com
TnMUC-1 (anti-TnMUC-1 CAR-T cell therapy)	Tmunity Therapeutics Philadelphia, PA	ovarian cancer, triple negative breast cancer	Phase I www.tmunity.com
Trodelvy® sacituzumab govitecan-hziy	Gilead Sciences Foster City, CA	HR+ HER2- metastatic breast cancer, 1L metastatic triple-negative breast cancer (PD-L1+), 1L metastatic triple negative breast cancer (PD-L1-)	Phase III www.gilead.com
TT11 (CAR-T cell therapy)	Tessa Therapeutics	Hodgkin lymphoma	Phase II www.tessacell.com
		CD30+ non-Hodgkin lymphoma	Phase I www.tessacell.com
TT-01488 (BTK inhibitor)	TransThera Sciences Nanjing, China	B-cell non-Hodgkin lymphoma	Phase I www.transtherabio.com

Cancer

Drug Name

Organization

Indication

Development Phase

TTI-101 (STAT3 inhibitor)	Tvardi Therapeutics Sugar Land, TX	HR+ HER2- breast cancer	Phase I/II www.tvarditherapeutics.com
Tukysa® tucatinib	Merck Whitehouse Station, NJ Seagen Bothell, WA	1L/2L metastatic HER2+ breast cancer, adjuvant high risk HER2+ breast cancer, 1L maintenance HER2+ metastatic breast cancer	Phase III www.seagen.com
		2L HER2+ metastatic breast cancer	Phase II www.seagen.com
tusamitamab ravtansine (anti-CEACAM5 ADC)	Sanofi Bridgewater, NJ	breast cancer	Phase II www.sanofi.com
TX05 (trastuzumab biosimilar)	Tanvex BioPharma Irvine, CA	breast cancer	application submitted www.tanvex.com
upifitamab rilsodotin (NaPi2b inhibitor)	Mersana Therapeutics Cambridge, MA	recurrent platinum sensitive ovarian cancer (maintenance) (Fast Track)	Phase III www.mersana.com
		platinum sensitive ovarian cancer	Phase II www.mersana.com
V937 (oncolytic virus vaccine)	Merck Whitehouse Station, NJ	breast cancer	Phase II www.merck.com

Cancer

<u>Drug Name</u>	<u>Organization</u>	<u>Indication</u>	<u>Development Phase</u>
veliparib (PARP inhibitor)	AbbVie North Chicago, CA	breast cancer, ovarian cancer	Phase III www.abbvie.com
Verzenio® abemaciclib	Lilly Indianapolis, IN	castration resistant prostate cancer, hormone sensitive prostate cancer, MBC sequencing	Phase III www.lilly.com
VERU-100 (GnRH antagonist)	Veru Miami, FL	hormone sensitive prostate cancer	Phase II www.verupharma.com
Veyonda® idronoxil	Noxopharm Gordon, Australia	metastatic castration-resistant prostate cancer	Phase I/II www.noxopharm.com
[vic]-trastuzumab duocarmazine (antibody drug conjugate)	Byondis Nijmegen, Netherlands	HER2+ metastatic breast cancer	application submitted www.byondis.com
Vigil® (genetically-modified autologous tumor cell vaccine and bi-shRNAfurin)	Gradalis Carrollton, TX	stage IIIb-IV ovarian cancer	Phase II www.gradalisinc.com
VIP-152 (CDK9 inhibitor)	Vincerx Pharma Palo Alto, CA	CLL, NHL	Phase I www.vincerx.com
voruciclib (CDK9 inhibitor)	MEI Pharma San Diego, CA	B-cell malignancies	Phase I www.meipharma.com

Cancer

Drug Name

Organization

Indication

Development Phase

VS-6766 (avutometinib)
(Raf/MEK inhibitor)

Verastem Oncology
Boston, MA

ovarian cancer (+defactinib)
(Breakthrough Therapy)

Phase II
www.verastem.com

VT101

Veana Therapeutics
Portland, OR

refractory HER2+ breast cancer

Phase I
www.veana-therapeutics.com

vudalimab
(PD-1 x CTLA-4 bispecific antibody)

Xencor
Monrovia, CA

metastatic castration resistant
prostate cancer

Phase II
www.xencor.com

Xpovio®
selinexor
ORPHAN DRUG

Karyopharm Therapeutics
New York, NY

DLBCL

Phase III
www.karyopharm.com

Xtandi®
enzalutamide

Astellas Pharma
Northbrook, IL
Pfizer
New York, NY

high-risk castration sensitive
prostate cancer (non-metastatic)

Phase III
www.pfizer.com

Yescarta®
axicabtagene ciloleucel

Kite Pharma (Gilead)
Santa Monica, CA

2L+ high-risk follicular lymphoma,
1L high-risk large B-cell lymphoma,
2L large B-cell lymphoma (out-
patient), 1L large B-cell lymphoma

Phase III
www.gilead.com

Cancer

Drug Name

Organization

Indication

Development Phase

zandelisib
(PI3K inhibitor)
ORPHAN DRUG

MEI Pharma
San Diego, CA

2L+ follicular lymphoma (Fast Track),
marginal zone lymphoma

Phase III
www.meipharma.com

2L+ CLL (combination therapy),
follicular lymphoma, marginal
zone lymphoma (monotherapy)

Phase II
www.meipharma.com

1L DLBCL

Phase I
www.meipharma.com

zanidatamab (ZW25)
(HER2 x HER2 bispecific antibody)

Zymeworks
Seattle, WA

HR+ HER2+ breast cancer

Phase II
www.zymeworks.com

Zejula®
niraparib

GlaxoSmithKline
Research Triangle Park, NC

1L maintenance ovarian cancer
(+dostarlimab), pre-metastatic
select biomarker population
breast cancer

Phase III
www.gsk.com

Janssen Research & Development
Raritan, NJ

L1 metastatic castration resistant
prostate cancer (+abiraterone
acetate and prednisone)
(Breakthrough Therapy)

application submitted
www.janssen.com

M1 metastatic castration-sensitive
prostate cancer (+abiraterone
acetate and prednisone)

www.janssen.com

Cancer

Drug Name

Organization

Indication

Development Phase

ZEN-3694
(BET inhibitor)

Zenith Epigenetics
San Francisco, CA

metastatic castration resistant
prostate cancer (combination
therapy), triple negative breast
cancer (combination therapy)

Phase II
www.zenithepigenetics.com

zilovertamab
(anti-ROR1 antibody)
ORPHAN DRUG

Oncternal Therapeutics
San Diego, CA

mantle cell lymphoma

Phase II
www.oncternal.com

breast cancer

Phase I
www.oncternal.com

zilovertamab vedotin (MK-2140)
(anti-ROR1 antibody drug conjugate)

Merck
Kenilworth, NJ

breast cancer, ovarian cancer,
CLL, DLBCL, follicular lymphoma,
mantle cell lymphoma

Phase II
www.oncternal.com

ZN-c3
(WEE1 inhibitor)

Zentalis Pharmaceuticals
New York, NY

ovarian cancer

Phase I/II
www.zentalis.com

ZN-c5
(SERD)

Zentalis Pharmaceuticals
New York, NY

breast cancer

Phase I/II
www.zentalis.com

zotatifin
(eIF4A inhibitor)

eFFECTOR Therapeutics
Solana Beach, CA

ER+ breast cancer

Phase II
www.effector.com

Cancer

<u>Drug Name</u>	<u>Organization</u>	<u>Indication</u>	<u>Development Phase</u>
ZX-101A (PI3K inhibitor)	Zenshine Pharmaceuticals Nanjing, China	CLL/SLL	Phase I/II www.zenshine-pharma.com
Zynlonta® loncastuximab tesirine-lpyl	ADC Therapeutics New Providence, NJ	DLBCL (+rituximab), follicular lymphoma	Phase II www.adctherapeutics.com

Cardiovascular Disease

<u>Drug Name</u>	<u>Organization</u>	<u>Indication</u>	<u>Development Phase</u>
3K3A-APC (recombinant activated protein C)	ZZ Biotech Houston, TX	ischemic stroke (Fast Track)	Phase III www.zzbiotech.com
abelacimab (factor XI/XIa inhibitor)	Anthos Therapeutics Cambridge, MA	stroke risk in atrial fibrillation	Phase II www.anthostherapeutics.com
APD418 (β3-adrenergic receptor antagonist and cardiac myotrope)	Pfizer New York, NY	heart failure with reduced ejection fraction (Fast Track)	Phase II www.pfizer.com
aprocitentan (endothelin receptor antagonist)	Janssen Research & Development Raritan, NJ	difficult to treat hypertension	Phase III www.janssen.com
ARO-ANG3 (ANGPTL3 inhibitor) ORPHAN DRUG	Arrowhead Pharmaceuticals Pasadena, CA	dyslipidemia	Phase II www.arrowheadpharma.com

Cardiovascular Disease

<u>Drug Name</u>	<u>Organization</u>	<u>Indication</u>	<u>Development Phase</u>
ARO-APOC3 (apolipoprotein C-III inhibitor)	Arrowhead Pharmaceuticals Pasadena, CA	hypertriglyceridemia	Phase III www.arrowheadpharma.com
AST-004 (A1R/A3R agonist)	Astrocyte Pharmaceuticals Groton, CT	stroke	Phase I www.astrocytepharma.com
asundexian (FXIa inhibitor)	Bayer Pharmaceuticals Whippany, NJ	stroke risk in atrial fibrillation, stroke prevention (Fast Track)	Phase II www.bayer.com
AZD0780	AstraZeneca Wilmington, DE	dyslipidemia	Phase I www.astrazeneca.com
AZD3427	AstraZeneca Wilmington, DE	heart failure	Phase I www.astrazeneca.com
AZD4831 (peroxidase inhibitor)	AstraZeneca Wilmington, DE	heart failure with preserved ejection fraction	Phase II www.astrazeneca.com
AZD5718 (atuliflapon) (5-lipoxygenase protein inhibitor)	AstraZeneca Wilmington, DE	coronary artery disease	Phase II www.astrazeneca.com
AZD8233 (PCSK9 inhibitor)	AstraZeneca Wilmington, DE	hypercholesterolemia	Phase II www.astrazeneca.com

Cardiovascular Disease

<u>Drug Name</u>	<u>Organization</u>	<u>Indication</u>	<u>Development Phase</u>
AZD9977 (mineralocorticoid receptor modulator)	AstraZeneca Wilmington, DE	heart failure with chronic kidney disease (+dapaglifozin)	Phase II www.astrazeneca.com
balovaptan (RG7314) (vasopressin-1 receptor antagonist)	Roche/Genentech South San Francisco, CA	ischemic stroke	Phase II www.roche.com
baxdrostat (CIN-107) (aldosterone synthase inhibitor)	CinCor Pharma Waltham, MA	treatment resistant hypertension, uncontrolled hypertension, hypertension in chronic kidney disease	Phase II www.cincor.com
bexagliflozin (SGLT2 inhibitor)	Theracos Marlborough, MA	essential hypertension	Phase II/III completed www.theracos.com
BIIB093 (IV glibenclamide) (SUR1-TRPM4 inhibitor) ORPHAN DRUG	Biogen Cambridge, MA	large hemispheric infarction (Fast Track)	Phase III www.biogen.com
BIIB131 (TMS-007) (plasminogen activator)	Biogen Cambridge, MA	stroke	Phase II www.biogen.com
Camzyos™ mavacamten	Bristol-Myers Squibb Princeton, NJ	heart failure with preserved ejection fraction	Phase II www.bms.com

Cardiovascular Disease

<u>Drug Name</u>	<u>Organization</u>	<u>Indication</u>	<u>Development Phase</u>
CardiALLO cell therapy (mesenchymal stem cell therapy)	BioCardia Sunnyvale, CA	ischemic heart failure	Phase II www.biocardia.com
CardiAMP cell therapy (mesenchymal stem cell therapy)	BioCardia Sunnyvale, CA	chronic myocardial ischemia, ischemic heart failure	Phase III www.biocardia.com
CRD-740 (PDE9 inhibitor)	Cardurion Pharmaceuticals Boston, MA	heart failure	Phase II www.cardurion.com
DM199 (tissue kallikrein replacement)	DiaMedica Therapeutics Minneapolis, MN	ischemic stroke (Fast Track)	Phase II www.diamedica.com
DTRI-031 (von Willebrand factor inhibitor)	Basking Biosciences Columbus, OH	ischemic stroke	Phase I www.baskingbiosciences.com
elezanumab (ABT-555) (RGMa inhibitor)	AbbVie North Chicago, IL	ischemic stroke	Phase II www.abbvie.com
epeleuton (DS102) (5-lipoxygenase inhibitor)	Afimmune Dublin, Ireland	hypertriglyceridemia (with type 2 diabetes)	Phase II www.afimmune.com
Farxiga [®] dapagliflozin	AstraZeneca Wilmington, DE	prevention of heart failure and cardiovascular death following a myocardial infarction, worsening heart failure or cardiovascular death in patients with chronic heart failure	Phase III www.astrazeneca.com

Cardiovascular Disease

<u>Drug Name</u>	<u>Organization</u>	<u>Indication</u>	<u>Development Phase</u>
firibastat (BAPAI inhibitor)	Quantum Genomics Paris, France	hypertension	Phase III www.quantum-genomics.com
Furoscix [®] furosemide controlled release	scPharmaceuticals Burlington, MA	chronic heart failure	application submitted www.scpharmaceuticals.com
GMRx2 (amlodipine/indapamide/telmisartan fixed-dose combination)	George Medicines London, United Kingdom	hypertension	Phase III www.george-medicines.com
GP531 (AMPK activator)	ViCardia Therapeutics San Francisco, CA	decompensated heart failure	Phase II www.vicardia.com
GSK3884464 (oral immunomodulator)	GlaxoSmithKline Research Triangle Park, NC	heart failure	Phase I www.gsk.com
HU6 (controlled metabolic accelerator)	Rivus Pharmaceuticals Charlottesville, VA	heart failure with preserved ejection fraction	Phase II www.rivuspharma.com
IMB-101 (pFOX inhibitor)	Imbria Pharmaceuticals Boston, MA	coronary artery disease	Phase II www.imbria.com
INL1 (chelating agent)	Innolife China	heart failure	Phase I www.innolife.com.cn

Cardiovascular Disease

<u>Drug Name</u>	<u>Organization</u>	<u>Indication</u>	<u>Development Phase</u>
invimestrocel (allogeneic stem cell therapy)	Athersys Cleveland, OH	ischemic stroke (Fast Track)	Phase III www.athersys.com
ION904 (angiotensinogen)	Ionis Pharmaceuticals Carlsbad, CA	treatment-resistant hypertension, congestive heart failure with reduced ejection fraction	Phase II www.ionispharma.com
IONIS-AGT-LRx (angiotensinogen)	Ionis Pharmaceuticals Carlsbad, CA	treatment-resistant hypertension, congestive heart failure with reduced ejection fraction	Phase II www.ionispharma.com
Jardiance [®] empagliflozin	Boehringer Ingelheim Ridgefield, CT Lilly Indianapolis, IN	heart failure post-MI	Phase III www.boehringer-ingelheim.com www.lilly.com
JK07 (HER3-NRG1 antibody fusion protein)	SalubrisBio Gaithersburg, MD	heart failure with preserved ejection fraction	Phase I www.salubrisbio.com
JTT-861 (PDHK inhibitor)	Japan Tobacco/Akros Pharma Princeton, NJ	chronic heart failure	Phase I www.akrospharma.com
Kerendia [®] finerenone	Bayer Pharmaceuticals Whippany, NJ	heart failure with mid-range preserved ejection fraction	Phase III www.bayer.com

Cardiovascular Disease

<u>Drug Name</u>	<u>Organization</u>	<u>Indication</u>	<u>Development Phase</u>
lenrispodun (ITI-214) (PDE1 inhibitor)	Intra-Cellular Therapies New York, NY	heart failure	Phase II www.intracellulartherapies.com
Leqvio [®] inclisiran	Novartis Pharmaceuticals East Hanover, NJ	hyperlipidemia (pediatric), secondary prevention of cardiovascular events in patients with elevated levels of LDL cholesterol	Phase III www.novartis.com
LIB003 (PCSK9 inhibitor)	LIB Therapeutics Cincinnati, OH	hypercholesterolemia	Phase III
LT3001 (free radical scavenger)	Lumosa Therapeutics Taipei, Taiwan	ischemic stroke	Phase II www.lumosa.com.tw
LTP001	Novartis East Hanover, NJ	pulmonary arterial hypertension	Phase I www.novartis.com
LY3461767 (NRG4 agonist) (neuregulin 4)	Lilly Indianapolis, IN	chronic heart failure	Phase I www.lilly.com
Lypdiso [™] ethyl eicosapentaenoic acid	Matinas BioPharma Bedminster, NJ	hypertriglyceridemia	Phase II www.matinasbiopharma.com
MANP (M-atrial natriuretic peptide)	E-Star BioTech New York, NY	resistant hypertension	Phase I

Cardiovascular Disease

<u>Drug Name</u>	<u>Organization</u>	<u>Indication</u>	<u>Development Phase</u>
MEDI6570 (oxLDL mAb modulator)	AstraZeneca Wilmington, DE	coronary heart disease	Phase II www.astrazeneca.com
mesenchymal stem cell therapy	Stemmedica Cell Technologies San Diego, CA	ischemic stroke	Phase I/II completed www.stemedica.com
milvexian (FXIa inhibitor)	Bristol-Myers Squibb Princeton, NJ Janssen Research & Development Raritan, NJ	secondary stroke prevention	Phase II www.bms.com www.janssen.com
MK-0616 (PCSK9 inhibitor)	Merck Kenilworth, NJ	hypercholesterolemia	Phase II www.merck.com
MK-5475 (sGC stimulant)	Merck Kenilworth, NJ	pulmonary arterial hypertension	Phase II www.merck.com
MLS-101 (aldosterone synthase inhibitor)	Mineralys Therapeutics Radnor, PA	resistant hypertension	Phase I www.mineralystx.com
Mounjaro [®] tirzepatide	Lilly Indianapolis, IN	heart failure with preserved ejection fraction, reduction of cardiovascular adverse outcomes in patients with type 2 diabetes	Phase III www.lilly.com

Cardiovascular Disease

<u>Drug Name</u>	<u>Organization</u>	<u>Indication</u>	<u>Development Phase</u>
NAN-101 (vector-enabled gene therapy)	Asklepios BioPharmaceutical Research Triangle Park, NC Bayer Whippany, NJ	congestive heart failure	Phase I www.askbio.com
NCS-01 (stem cell replacement therapy)	NC Medial Research Tokyo, Japan	ischemic stroke	Phase I/II www.ncmr.co.jp/en
nerinetide (NA-1) (PDZ domain inhibitor)	NoNO Toronto, Canada	acute stroke	Phase III www.nonoinc.ca
NNC-0385-0434 (oral PCSk9i inhibitor)	Novo Nordisk Plainsboro, NJ	hypercholesterolemia	Phase II www.novonordisk.com
obicetrapib (CETP inhibitor)	NewAmsterdam Pharma Naarden, The Netherlands	hypercholesterolemia	Phase III www.newamsterdampharma.com
olezarsen (apolipoprotein C-III inhibitor)	Ionis Pharmaceuticals Carlsbad, CA	hypertriglyceridemia	Phase III www.ionispharma.com
olpasiran (siRNA)	Amgen Thousand Oaks, CA	atherosclerotic cardiovascular disease	Phase II www.amgen.com
omecamtiv mecarbil (cardiac myosin stimulant)	Cytokinetics South San Francisco, CA	chronic heart failure (Fast Track)	application submitted www.cytokinetics.com

Cardiovascular Disease

<u>Drug Name</u>	<u>Organization</u>	<u>Indication</u>	<u>Development Phase</u>
Opsumit® macitentan	Janssen Research & Development Raritan, NJ	pulmonary arterial hypertension 75mg, chronic thromboembolic pulmonary hypertension 75mg, pulmonary arterial hypertension (+ tadalafil), pulmonary arterial hypertension (pediatric)	Phase III www.janssen.com
pegozafermin (BIO89-100) (FGF21 agonist)	89bio San Francisco, CA	hypertriglyceridemia	Phase II www.89bio.com
PP-007 (PEGylated hemoglobin/carbon monoxide)	Prolong Pharmaceuticals South Plainfield, NJ	ischemic stroke	Phase I www.prolongpharma.com
pelacarsen (TQJ230) (apolipoprotein A inhibitor)	Novartis Pharmaceuticals East Hanover, NJ	hyperlipoproteinemia (Fast Track)	Phase III www.novartis.com
PL3994 (NPR-A agonist)	Palatin Technologies Cranbury, NJ	heart failure	Phase II www.palatin.com
ponsegromab (PF-06946860) (GDF15 mAb inhibitor)	Pfizer New York, NY	heart failure	Phase I www.pfizer.com

Cardiovascular Disease

<u>Drug Name</u>	<u>Organization</u>	<u>Indication</u>	<u>Development Phase</u>
Praluent [®] alirocumab	Regeneron Tarrytown, NY Sanofi Wilmington, DE	heterozygous familial hypercholesterolemia (pediatric)	Phase III www.regeneron.com www.sanofi.com
PRM-125 (antihypertensive)	PRM Pharma Spring Hill, FL	hypertension	Phase III
prostacyclin receptor agonist	Janssen Research & Development Raritan, NJ	pulmonary arterial hypertension	Phase I www.janssen.com
REG-101 (cholesterol modulator)	Regio Biosciences Rockville, MD	coronary artery disease, peripheral vascular disease	Phase II www.regiobiosciences.com
REGN5381/REGN9035 (NPR1 agonist/REGN5381 reversal agent)	Regeneron Tarrytown, NY	heart failure	Phase I www.regeneron.com
relaxin-LA (relaxin replacement)	Lilly Indianapolis, IN	heart failure	Phase I www.lilly.com
Repatha [®] evolocumab	Amgen Thousand Oaks, CA	hypercholesterolemia, treatment of high-risk cardiovascular disease without prior heart attack or stroke	Phase III www.amgen.com

Cardiovascular Disease

<u>Drug Name</u>	<u>Organization</u>	<u>Indication</u>	<u>Development Phase</u>
rexlemestrocel-L (mesenchymal precursor cell therapy) ORPHAN DRUG	Mesoblast New York, NY	chronic heart failure with reduced ejection fraction	Phase III www.mesoblast.com
RMJH-111B (magnesium citrate)	RMJ Holdings Ashburn, VA	essential hypertension	Phase II completed www.rmjholdings.com
RNS60 (intracellular signaling pathway activator)	Revalesio Tacoma, WA	stroke	Phase II www.revalesio.com
rodatristat ethyl (tryptophan hydroxylase inhibitor)	Altavant Sciences Cary, NC	pulmonary arterial hypertension	Phase I www.altavant.com
ROMK inhibitor	Bristol-Myers Squibb Princeton, NJ	heart failure	Phase I www.bms.com
RP5063 (brilaroxazine) (dopamine/serotonin)	Reviva Pharmaceuticals Cupertino, CA	pulmonary arterial hypertension	Phase I www.revivapharma.com
SLN360 (apolipoprotein A inhibitor)	Silence Therapeutics London, United Kingdom	dyslipidemia, hyperlipidemia	Phase I www.silence-therapeutics.com
sotagliflozin (SGLT1/SGLT2 inhibitor)	Lexicon Pharmaceuticals The Woodlands, TX	heart failure	application submitted www.lexiconpharma.com

Cardiovascular Disease

<u>Drug Name</u>	<u>Organization</u>	<u>Indication</u>	<u>Development Phase</u>
sotatercept (MK-7962) (activin inhibitor)	Merck Whitehouse Station, NJ	pulmonary arterial hypertension	Phase III www.merck.com
SZ002 (MRA) (diuretic)	Sarfez Pharmaceuticals Vienna, VA	heart failure with preserved ejection fraction	in clinical trials www.sarfezpharma.com
SZ003 (diuretic/SGLT2i)	Sarfez Pharmaceuticals Vienna, VA	heart failure with preserved ejection fraction, heart failure with reserved ejection fraction	in clinical trials www.sarfezpharma.com
SZ004 (SGLT2i/MRA)	Sarfez Pharmaceuticals Vienna, VA	heart failure/dyspnea	in clinical trials www.sarfezpharma.com
TNX-102 (oral levosimendan)	Tenax Therapeutics Morrisville, NC	pulmonary hypertension, heart failure with preserved ejection fraction	Phase II completed www.tenaxthera.com
TNX-103 (subcutaneous levosimendan)	Tenax Therapeutics Morrisville, NC	pulmonary hypertension, heart failure with preserved ejection fraction	Phase II completed www.tenaxthera.com
TNX-201 (oral levosimendan)	Tenax Therapeutics Morrisville, NC	pulmonary arterial hypertension	Phase II www.tenaxthera.com
tonlamarsen (RNA interference)	Ionis Pharmaceuticals Carlsbad, CA	hypertension	Phase II www.ionispharma.com

Cardiovascular Disease

<u>Drug Name</u>	<u>Organization</u>	<u>Indication</u>	<u>Development Phase</u>
treprostinil palmitil inhalation powder	Insmed Bridgewater, NJ	pulmonary arterial hypertension	Phase II www.insmed.com
TT-00920 (PDE9A inhibitor)	TransThera Biosciences Nanjing, China	heart failure	Phase I www.thranstherabio.com
Uptravi® selexipag	Janssen Research & Development Raritan, NJ	pulmonary arterial hypertension (pediatric)	Phase III www.janssen.com
Verquvo® veriguat	Bayer Whippany, NJ	heart failure with reserved ejection fraction	Phase III www.bayer.com
XXB750 (subcutaneous)	Novartis Pharmaceuticals East Hanover, NJ	heart failure with preserved ejection fraction	Phase I www.novartis.com
zilebesiran (RNA interference)	Alnylam Pharmaceuticals Cambridge, MA	hypertension	Phase II www.alnylam.com
ziltivekimab (IL-6 inhibitor)	Novo Nordisk Plainsboro, NJ	reduce risk of cardiovascular events in patients with cardiovascular disease chronic kidney disease and inflammation	Phase III www.novonordisk.com

Chronic Kidney Disease

<u>Drug Name</u>	<u>Organization</u>	<u>Indication</u>	<u>Development Phase</u>
ALLN-346 (urate oxidase replacement)	Allena Pharmaceuticals Newton, MA	chronic kidney disease	Phase II www.allenapharma.com
AR882 (SLC22A12 protein inhibitor)	Arthrosi Therapeutics San Diego, CA	chronic kidney disease	Phase I www.arthrosi.com
AZD5718 (atuliflapon) (5-lipoxygenase protein inhibitor)	AstraZeneca Wilmington, DE	chronic kidney disease	Phase II www.astrazeneca.com
bardoxolone (Nrf2 activator) ORPHAN DRUG	Reata Pharmaceuticals Plano, TX	chronic kidney disease caused by Alport syndrome	application submitted www.reatapharma.com
		chronic kidney disease caused by autosomal dominant polycystic kidney disease, advanced chronic kidney disease and diabetes	Phase III www.reatapharma.com
BI 685509 (sGC activator)	Boehringer Ingelheim Ridgefield, CT	chronic kidney disease	Phase II www.boehringer-ingelheim.com
BI 690517 (hemodynamic modulator)	Boehringer Ingelheim Ridgefield, CT	chronic kidney disease	Phase II www.boehringer-ingelheim.com
CLBS201 (cell replacement therapy)	Caladrius Biosciences Basking Ridge, NJ	diabetic kidney disease	Phase I www.caladrius.com

Chronic Kidney Disease

<u>Drug Name</u>	<u>Organization</u>	<u>Indication</u>	<u>Development Phase</u>
cotadutide (GLP1/glucagon receptor agonist)	AstraZeneca Wilmington, DE	diabetic kidney disease	Phase II www.astrazeneca.com
CSL346 (VEGF-B inhibitor)	CSL Behring King of Prussia, PA	diabetic kidney disease	Phase II www.cslbehring.com
daprodustat (prolyl hydroxylase inhibitor)	GlaxoSmithKline Research Triangle Park, NC	chronic kidney disease	application submitted www.gsk.com
DM199 (tissue kallikrein replacement)	DiaMedica Therapeutics Minneapolis, MN	chronic kidney disease in African Americans	Phase II www.diamedica.com
GFB-024 (CB1 inverse agonist)	Goldfinch Bio Cambridge, MA	diabetic nephropathy	Phase I www.goldfinchbio.com
GFB-887 (TRPC5 ion channel inhibitor)	Goldfinch Bio Cambridge, MA	diabetic nephropathy	Phase II www.goldfinchbio.com
ION532 (APOL1)	Ionis Pharmaceuticals Carlsbad, CA	chronic kidney disease	Phase I www.ionispharma.com
Jardiance [®] empagliflozin	Boehringer Ingelheim Ridgefield, CT Lilly Indianapolis, IN	chronic kidney disease (Fast Track)	Phase III www.boehringer-ingelheim.com www.lilly.com

Chronic Kidney Disease

<u>Drug Name</u>	<u>Organization</u>	<u>Indication</u>	<u>Development Phase</u>
Kerendia [®] finerenone	Bayer Pharmaceuticals Whippany, NJ	chronic kidney disease (non-diabetic)	Phase III www.bayer.com
lokelma (potassium binding modulator)	AstraZeneca Wilmington, DE	hyperkalemia in chronic kidney disease	Phase III www.astrazeneca.com
MEDI8367	AstraZeneca Wilmington, DE	chronic kidney disease	Phase I www.astrazeneca.com
REACT [®] autologous cultured kidney tissue cell therapy	ProKidney Winston-Salem, NC	chronic kidney disease with type 2 diabetes	Phase III www.prokidney.com
roxadustat (HIF-PH inhibitor)	AstraZeneca Wilmington, DE FibroGen San Francisco, CA	anemia in chronic kidney disease	Phase III www.astrazeneca.com www.fibrogen.com
runcaciguat (sGC activator)	Bayer Pharmaceuticals Whippany, NJ	chronic kidney disease	Phase II www.bayer.com
tenapanor (phosphate absorption inhibitor)	Ardelyx Fremont, CA	hyperphosphatemia in chronic kidney disease	application submitted www.ardelyx.com
tozorakimab (IL-33 inhibitor)	AstraZeneca Wilmington, DE	diabetic kidney disease	Phase II www.astrazeneca.com

Chronic Kidney Disease

<u>Drug Name</u>	<u>Organization</u>	<u>Indication</u>	<u>Development Phase</u>
US-APR2020 (live biotherapeutic)	Kibow Biotech Newtown Square, PA	stage IV chronic kidney disease	Phase II/III www.kibowbiotech.com
vadadustat (HIF-PH inhibitor)	Akebia Therapeutics Cambridge, MA	anemia in chronic kidney disease	application submitted www.akebia.com
zibotentan (endothelin A antagonist)	AstraZeneca Wilmington, DE	chronic kidney disease (+dapagliflozin)	Phase II www.astrazeneca.com

Diabetes

<u>Drug Name</u>	<u>Organization</u>	<u>Indication</u>	<u>Development Phase</u>
AER-501 (human insulin inhalation)	Aerami Therapeutics Durham, NC	type 2 diabetes, type 1 diabetes	Phase I/II completed www.aerami.com
Afrezza [®] insulin human, inhalation powder	MannKind Danbury, CT	type 1 diabetes, type 2 diabetes (pediatric)	Phase III www.mannkindcorp.com
AG019 (ActoBiotics delivering the auto- antigen proinsulin and IL-10)	Precigen Germantown, MD	type 1 diabetes	Phase II www.precigen.com

Diabetes

<u>Drug Name</u>	<u>Organization</u>	<u>Indication</u>	<u>Development Phase</u>
ANJ9000 (metformin delayed release)	Anji Pharma Cambridge, MA	type 2 diabetes	Phase III www.anjipharma.com
AT247 (ultra-rapid acting insulin aspart)	Arecor Little Chesterford, United Kingdom	type 1 diabetes	Phase I www.arecor.com
AVT001 (dendritic cell therapy)	Avotres Cedar Knolls, NJ	type 1 diabetes	Phase I www.avotres.com
Baqsimi [®] glucagon intranasal	Lilly Indianapolis, IN	type 1 diabetes (pediatric)	Phase I www.lilly.com
bexagliflozin (SGLT2 inhibitor)	Theracos Marlborough, MA	type 2 diabetes	Phase III www.theracos.com
CagriSema (amylin analogue/semaglutide)	Novo Nordisk Plainsboro, NJ	type 2 diabetes	Phase II www.novonordisk.com
cotadutide (GLP1/glucagon receptor agonist)	AstraZeneca Wilmington, DE	type 2 diabetes	Phase II www.astrazeneca.com
CPP-1X (eflornithine)	Panbela Therapeutics Minneapolis, MN	recent onset type 1 diabetes	Phase I www.panbela.com

Diabetes

Drug Name

Organization

Indication

Development Phase

CT-388
(GLP1/GIP dual receptor modulator)

Carmot Therapeutics
Berkeley, CA

type 2 diabetes

Phase I
www.carmot-therapeutics.us

CT-868
(GLP1/GIP dual receptor modulator)

Carmot Therapeutics
Berkeley, CA

type 1 diabetes, type 2 diabetes

Phase I
www.carmot-therapeutics.us

danuglipron (PF-06882961)
(GLP1R agonist)

Pfizer
New York, NY

type 2 diabetes

Phase II
www.pfizer.com

dasiglucagon for bi-hormonal
artificial pancreas systems

Zealand Pharma
Boston, MA

type 1 diabetes
management

Phase III
www.zealandpharma.com

dasiglucagon low dose pen

Zealand Pharma
Boston, MA

type 1 diabetes exercise-
induced hypoglycemia

Phase II
www.zealandpharma.com

diabetes therapeutic

Lilly
Indianapolis, IN

diabetes

Phase I
www.lilly.com

DNA immunotherapy
(plasmid encoding pre- and
pro-insulin)

Novo Nordisk
Plainsboro, NJ

type 1 diabetes (preservation
of beta cell function)

Phase I
www.novonordisk.com

epeleton (DS102)
(5-lipoxygenase inhibitor)

Afimmune
Dublin, Ireland

type 2 diabetes
(with hypertriglyceridemia)

Phase II
www.afimmune.com

Diabetes

Drug Name

Organization

Indication

Development Phase

Farxiga®
dapagliflozin

AstraZeneca
Wilmington, DE

type 2 diabetes (pediatric)

Phase III
www.astrazeneca.com

FDC Sema—OWGIP
(semaglutide/GIP)

Novo Nordisk
Plainsboro, NJ

type 2 diabetes

Phase II
www.novonordisk.com

glucagon/insulin
fixed-dose combination

Abvance Therapeutics
Carlsbad, CA

type 2 diabetes

Phase I
www.abvancetherapeutics.com

glucose sensitive insulin

Novo Nordisk
Plainsboro, NJ

type 1 diabetes, type 2 diabetes

Phase I
www.novonordisk.com

GLY-200
(oral gut-restricted polymer)

Glyscend Therapeutics
Lowell, MA

type 2 diabetes

Phase I
www.glyscend.com

GZR18
(GLP1 agonist)

Gan & Lee Pharmaceuticals USA
Bridgewater, NJ

type 2 diabetes

Phase I
www.ganlee.us

HU6
(controlled metabolic accelerator)

Rivus Pharmaceuticals
Charlottesville, VA

type 2 diabetes

Phase II
www.rivuspharma.com

Icosema
(insulin icodec/semaglutide)

Novo Nordisk
Plainsboro, NJ

type 2 diabetes

Phase III
www.novonordisk.com

Diabetes

<u>Drug Name</u>	<u>Organization</u>	<u>Indication</u>	<u>Development Phase</u>
ideal pump insulin (insulin analogue in a closed loop device)	Novo Nordisk Plainsboro, NJ	type 1 diabetes	Phase I www.novonordisk.com
IMT-002 (HLA-DQ8 antigen inhibitor) ORPHAN DRUG	IM Therapeutics Woburn, MA	type 1 diabetes	Phase I www.imtherapeutics.com
INS068 (insulin degludec)	Jiangsu Hengrui Medicine Jiangsu, China	type 2 diabetes	Phase II www.hengrui.com
insulin 965 (basal insulin analogue)	Novo Nordisk Plainsboro, NJ	type 1 diabetes, type 2 diabetes	Phase I www.novonordisk.com
insulin icodec (long-acting basal insulin analogue)	Novo Nordisk Plainsboro, NJ	type 1 diabetes, type 2 diabetes	Phase III www.novonordisk.com
IONIS-GCGR _{RX} (GCGR inhibitor)	Ionis Pharmaceuticals Carlsbad, CA	type 2 diabetes	Phase II www.ionispharma.com
iscalimab (CFZ533) (CD40 inhibitor)	Novartis Pharmaceuticals East Hanover, NJ	type 1 diabetes	Phase II www.novartis.com
IVA337 (PPA modulator)	Inventiva Pharma Daix, France	type 2 diabetes with NASH (+empagliflozin)	Phase II www.inventivapharma.com

Diabetes

Drug Name

Organization

Indication

Development Phase

Jardiance® empagliflozin	Boehringer Ingelheim Ridgefield, CT Lilly Indianapolis, IN	type 2 diabetes (pediatric)	Phase III www.boehringer-ingelheim.com www.lilly.com
KHK inhibitor	Lilly Indianapolis, IN	diabetes	Phase I www.lilly.com
LX2761 (SGLT2 inhibitor)	Lexicon Pharmaceuticals The Woodlands, TX	type 2 diabetes	Phase I completed www.lexpharma.com
LY3209590 (basal insulin-Fc)	Lilly Indianapolis, IN	type 2 diabetes, type 1 diabetes	Phase III www.lilly.com
LY3437943 (retatrutide) (GGG tri-agonist)	Lilly Indianapolis, IN	type 2 diabetes	Phase II www.lilly.com
LY3457263 (peptide YY)	Lilly Indianapolis, IN	type 2 diabetes	Phase I www.lilly.com
LY3493269 (GIP/GLP coagonist peptide)	Lilly Indianapolis, IN	type 2 diabetes	Phase I www.lilly.com
LY3502970 (GLP1 receptor NPA)	Lilly Indianapolis, IN	type 2 diabetes	Phase II www.lilly.com

Diabetes

<u>Drug Name</u>	<u>Organization</u>	<u>Indication</u>	<u>Development Phase</u>
LY3532226 (GIPR agonist long acting)	Lilly Indianapolis, IN	type 2 diabetes	Phase I www.lilly.com
LY3537021 (GIPR agonist long acting)	Lilly Indianapolis, IN	type 2 diabetes	Phase I www.lilly.com
mazdutide (oxyntomodulin)	Lilly Indianapolis, IN	diabetes	Phase I www.lilly.com
MBX-2982 (GPR 119 agonist)	CymaBay Therapeutics Newark, CA	diabetic hypoglycemia	Phase II www.cymabay.com
Mounjaro [®] tirzepatide	Lilly Indianapolis, IN	type 2 diabetes (pediatric)	Phase III www.lilly.com
MYL-1601D (insulin aspart biosimilar)	Viatrix Canonsburg, PA	type 1 diabetes	Phase III completed www.viatrix.com
Nesina [®] alogliptin	Takeda Lexington, MA	type 2 diabetes (pediatric)	Phase III completed www.takeda.com
Onglyza [®] saxagliptin	AstraZeneca Wilmington, DE	type 2 diabetes (pediatric)	Phase III www.astrazeneca.com

Diabetes

<u>Drug Name</u>	<u>Organization</u>	<u>Indication</u>	<u>Development Phase</u>
OPK8803 (GLP1/glucagon receptor agonist)	OPKO Health Miami, FL	type 2 diabetes	Phase II www.opko.com
ORMD-0801 (insulin oral)	Oramed Pharmaceuticals New York, NY	type 2 diabetes	Phase III www.oramed.com
ORMD-0901 (oral GLP1)	Oramed Pharmaceuticals New York, NY	type 2 diabetes	Phase I www.oramed.com
PEC-Direct (VC02) (pancreatic beta cell replacement)	ViaCyte San Diego, CA	high-risk type 1 diabetes	Phase I/II www.viacyte.com
PEC-Encap (VC-01) (pancreatic beta cell replacement)	ViaCyte San Diego, CA	high-risk type 1 diabetes	Phase I/II www.viacyte.com
PF-07081532 (GLP1R agonist)	Pfizer New York, NY	type 2 diabetes	Phase I www.pfizer.com
REMD-477 (volagidemab) (GPCR antagonist)	REMD Biotherapeutics Camarillo, CA	type 1 diabetes, type 2 diabetes	Phase II www.remdbio.com
RGT-075 (GLP1 agonist)	Regor Therapeutics Cambridge, MA	type 2 diabetes	Phase II www.regor.com

Diabetes

Drug Name

Organization

Indication

Development Phase

Rybelsus®
semaglutide tablets (oral)

Novo Nordisk
Plainsboro, NJ

type 2 diabetes (once-weekly)

application submitted
www.novonordisk.com

type 2 diabetes (pediatric),
type 2 diabetes (25mg and 50mg)

Phase III
www.novonordisk.com

sotagliflozin
(SGLT1 / SGLT2 inhibitor)

Lexicon Pharmaceuticals
The Woodlands, TX

type 1 diabetes

Phase III
www.lexpharma.com

Steglatro®
ertugliflozin

Merck
Kenilworth, NJ

type 2 diabetes (pediatric)

Phase III
www.merck.com

teplizumab
(CD3 antigen inhibitor)
ORPHAN DRUG

Provention Bio
Red Bank, NJ

type 1 diabetes (delay of clinical
disease in at-risk patients)
(Breakthrough Therapy)

application submitted
www.proventbio.com

type 1 diabetes (newly-diagnosed)

Phase III
www.proventbio.com

tolimidone
(Lyn protein-tyrosine kinase
stimulant)

Melior Pharmaceuticals
Exton, PA

type 2 diabetes

Phase II
www.meliorpharmaceuticals.com

Tradjenta®
linagliptin

Boehringer Ingelheim
Ridgefield, CT

type 2 diabetes (pediatric)

Phase III
www.boehringer-ingelheim.com

Diabetes

<u>Drug Name</u>	<u>Organization</u>	<u>Indication</u>	<u>Development Phase</u>
TTP273 (GLP1R agonist)	VTV Therapeutics High Point, NC	type 2 diabetes	Phase II www.vtvtherapeutics.com
TTP399 (GK activator)	VTV Therapeutics High Point, NC	type 1 diabetes (Breakthrough Therapy)	Phase II www.vtvtherapeutics.com
VCTX210 (CRISPR/Cas9 gene-edited stem cell therapy)	CRISPR Therapeutics Cambridge, MA ViaCyte San Diego, CA	type 1 diabetes	Phase I www.crisprtx.com www.viacyte.com
VK0612 (FBPase inhibitor)	Viking Therapeutics San Diego, CA	type 2 diabetes	Phase II www.vikingtherapeutics.com
VX-880 (insulin-producing islet cell therapy)	Vertex Pharmaceuticals Boston, MA	type 1 diabetes (Fast Track)	Phase I/II www.vrtx.com
YG1699 (SGLT1 / SGLT2 inhibitor)	Youngene Therapeutics Shanghai, China	type 1 diabetes	Phase II www.youngene.com

Gastrointestinal Disorders

<u>Drug Name</u>	<u>Organization</u>	<u>Indication</u>	<u>Development Phase</u>
ABP 654 (ustekinumab biosimilar)	Amgen Thousand Oaks, CA	Crohn's disease	Phase III www.amgen.com
ABBV-154 (anti-TNF GRM ADC)	AbbVie North Chicago, IL	Crohn's disease	Phase II www.abbvie.com
AVT02 (adalimumab biosimilar)	Alvotech Reykjavik, Iceland	Crohn's disease, ulcerative colitis	application submitted www.alvotech.com
ADS024 (live biotherapeutic product)	Adiso Therapeutics San Diego, CA	ulcerative colitis	Phase II www.adisotx.com
ADS051 (neutrophil modulator)	Adiso Therapeutics San Diego, CA	ulcerative colitis	Phase I www.adisotx.com
Alofisel [®] darvadstrocel	Takeda Lexington, MA	perianal fistulas in Crohn's disease (adults and pediatric)	Phase III www.takeda.com
amiselimod (S1P2 modulator)	Salix Pharmaceuticals Bridgewater, NJ	ulcerative colitis	Phase II www.salix.com
AT-177 (AhR agonist)	Azora Therapeutics Los Angeles, CA	ulcerative colitis	Phase I www.azoratherapeutics.com

Gastrointestinal Disorders

<u>Drug Name</u>	<u>Organization</u>	<u>Indication</u>	<u>Development Phase</u>
AMT-101 (IL-10 replacement)	Applied Molecular Transport South San Francisco, CA	chronic pouchitis, ulcerative colitis	Phase II www.appliedmt.com
AVT02 (adalimumab biosimilar)	Alvotech Reykjavik, Iceland	Crohn's disease, pediatric Crohn's disease, ulcerative colitis, pediatric ulcerative colitis	application submitted www.alvotech.com
BI 706321 (phosphotransferase inhibitor)	Boehringer Ingelheim Ridgefield, CT	Crohn's disease	Phase II www.boehringer-ingelheim.com
blautix (live bacterial product)	4D Pharma Leeds, United Kingdom	irritable bowel syndrome	Phase II completed www.4dpharmapl.com
brazikumab (IL-23 subunit p19 inhibitor)	AstraZeneca Wilmington, DE	Crohn's disease	Phase III www.astrazeneca.com
		ulcerative colitis	Phase II www.astrazeneca.com
brilacidin (defensin biomimetic)	Innovation Pharmaceuticals Wakefield, MA	ulcerative proctitis/ulcerative proctosigmoiditis	Phase II www.ipharminc.com
		ulcerative colitis	Phase I www.ipharminc.com

Gastrointestinal Disorders

<u>Drug Name</u>	<u>Organization</u>	<u>Indication</u>	<u>Development Phase</u>
CBP-307 (S1P1/S1P5 agonist)	Connect Biopharma San Diego, CA	ulcerative colitis	Phase II www.connectbiopharm.com
CCX507 (CCR9 receptor antagonist)	ChemoCentryx San Carlos, CA	ulcerative colitis	Phase I www.chemoentryx.com
CIN-103 (phenol-derivative)	Cinphlora Cincinnati, OH	irritable bowel syndrome	Phase I completed www.conphlora.com
deucravacitinib (TYK2 kinase inhibitor)	Bristol-Myers Squibb Princeton, NJ	Crohn's disease, ulcerative colitis	Phase II www.bms.com
EcoActive bacteriophage preparation	Intralytix Columbia, MD	Crohn's disease	Phase I/II www.intralytix.com
efavaleukin alfa (IL-2 mutein Fc fusion protein)	Amgen Thousand Oaks, CA	ulcerative colitis	Phase II www.amgen.com
Entyvio® vedolizumab	Takeda Lexington, MA	Crohn's disease (pediatric), ulcerative colitis (pediatric), Crohn's disease (subcutaneous)	Phase III www.takeda.com

Gastrointestinal Disorders

<u>Drug Name</u>	<u>Organization</u>	<u>Indication</u>	<u>Development Phase</u>
etrasimod (SP1 inhibitor)	Pfizer New York, NY	ulcerative colitis	Phase III www.pfizer.com
		Crohn's disease	Phase II www.pfizer.com
GS-1427 (alpha4beta7 inhibitor)	Gilead Sciences Foster City, CA	inflammatory bowel disease	Phase I www.gilead.com
GS-5290 (TPL2 inhibitor)	Gilead Sciences Foster City, CA	inflammatory bowel disease	Phase I www.gilead.com
GS-5817 (IRAK4 inhibitor)	Gilead Sciences Foster City, CA	inflammatory bowel disease	Phase I www.gilead.com
Hadlima® adalimumab-bwwd (citrate-free, high-concentration)	Organon Jersey City, NJ Samsung Bioepis Incheon, South Korea	Crohn's disease, ulcerative colitis	application submitted www.samsungbioepis.com
IMC-1 (famciclor + celecoxib)	Virios Therapeutics Alpharetta, GA	irritable bowel syndrome	Phase II www.virios.com
JNJ-4804	Janssen Research & Development Raritan, NJ	ulcerative colitis (combination therapy)	Phase II www.janssen.com

Gastrointestinal Disorders

<u>Drug Name</u>	<u>Organization</u>	<u>Indication</u>	<u>Development Phase</u>
JNJ-9280	Janssen Research & Development Raritan, NJ	inflammatory bowel disease	Phase I www.janssen.com
Linzess® linaclotide	AbbVie North Chicago, IL Ironwood Pharmaceuticals Boston, MA	irritable bowel syndrome (pediatric)	Phase III www.abbvie.com
LYS006 (LTA4 hydrolase inhibitor)	Novartis Pharmaceuticals East Hanover, NJ	ulcerative colitis	Phase II www.novartis.com
mirikizumab (IL-23 subunit p19 inhibitor)	Lilly Indianapolis, IN	ulcerative colitis	application submitted www.lilly.com
		Crohn's disease	Phase III www.lilly.com
MK-6194 (IL-2 replacement/regulatory T-lymphocyte stimulant)	Merck Kenilworth, NJ	ulcerative colitis	Phase I www.merck.com
MORF-057 (alpha4beta7 integrin antagonist)	Morphic Therapeutic Waltham, MA	Crohn's disease, ulcerative colitis	Phase II www.morphictx.com

Gastrointestinal Disorders

<u>Drug Name</u>	<u>Organization</u>	<u>Indication</u>	<u>Development Phase</u>
niclosamide (FW-UP) (anti-inflammatory inhibitor)	First Wave Bio Boca Raton, FL	ulcerative proctitis, ulcerative proctosigmoiditis	Phase II www.firstwavebio.com
NX-13 (NLRX1 agonist)	Landos Biopharma Blacksburg, VA	ulcerative colitis	Phase I completed www.landosbiopharma.com
omilancor (LANCL2 agonist)	Landos Biopharma Blacksburg, VA	ulcerative colitis	Phase II www.landosbiopharma.com
ORP-101 (opioid kappa receptor antagonist/ opioid mu receptor agonist)	OrphoMed San Francisco, CA	irritable bowel syndrome (Fast Track)	Phase II www.orphomed.com
OSSM-001 (mesenchymal stem cell therapy)	Ossium Health San Francisco, CA	perianal fistulizing Crohn's disease	Phase I www.ossiumhealth.com
PB006 (natalizumab biosimilar)	Polpharma Biologics Gdansk, Poland Sandoz Princeton, NJ	Crohn's disease	application submitted www.sandoz.com
PF-06480605 (TNFSF15 blocker)	Pfizer New York, NY	ulcerative colitis	Phase II www.pfizer.com

Gastrointestinal Disorders

<u>Drug Name</u>	<u>Organization</u>	<u>Indication</u>	<u>Development Phase</u>
PF-07054894 (CCR6 antagonist)	Pfizer New York, NY	inflammatory bowel disease	Phase I www.pfizer.com
PL8177 (oral MC1r agonist)	Palatin Technologies Cranbury, NJ	ulcerative colitis	Phase II www.palatin.com
PN-943 (alpha4beta7 integrin antagonist)	Protagonist Therapeutics Newark, CA	ulcerative colitis	Phase II www.protagonist-inc.com
PRA023 (anti-TL1A mAb)	Prometheus Biosciences San Diego, CA	Crohn's disease, ulcerative colitis	Phase II www.prometheusbiosciences.com
RBX2660 (gastrointestinal microbiome modulator)	Rebiotix Roseville, MN	ulcerative colitis (pediatric)	Phase I www.rebiotix.com
remestemcel-L (mesenchymal precursor cell therapy)	Mesoblast New York, NY	biologic refractory Crohn's disease (Fast Track), ulcerative colitis	Phase II www.mesoblast.com
RG6287	Roche/Genentech South San Francisco, CA	inflammatory bowel disease	Phase I www.roche.com
RHB-104 (clarithromycin/clofazimine/rifabutin)	RedHill Biopharma Raleigh, NC	Crohn's disease	Phase III completed www.redhillbio.com

Gastrointestinal Disorders

<u>Drug Name</u>	<u>Organization</u>	<u>Indication</u>	<u>Development Phase</u>
Rinvoq® upadacitinib	AbbVie North Chicago, IL	Crohn's disease	application submitted www.abbvie.com
ritlecitinib (JAK3/TEC inhibitor)	Pfizer New York, NY	Crohn's disease, ulcerative colitis	Phase III www.pfizer.com
SGX-203 (beclometasone oral) ORPHAN DRUG	Soligenix Princeton, NJ	pediatric Crohn's disease (Fast Track)	Phase II www.soligenix.com
SHR0302 (JAK1 inhibitor)	Reistone Biopharma Boston, MA	ulcerative colitis	Phase III www.reistonebio.com
		Crohn's disease	Phase II completed www.reistonebio.com
sibofimloc (microbiome modulator)	Takeda Lexington, MA	post-operative Crohn's disease	Phase II www.takeda.com
		luminal Crohn's disease	Phase I www.takeda.com
Simponi® golimumab	Janssen Research & Development Raritan, NJ	ulcerative colitis (pediatric)	Phase III www.janssen.com

Gastrointestinal Disorders

<u>Drug Name</u>	<u>Organization</u>	<u>Indication</u>	<u>Development Phase</u>
Skyrizi® risankizumab	AbbVie North Chicago, IL	ulcerative colitis	Phase III www.abbvie.com
SPH3127 (renin inhibitor)	Shanghai Pharma Biotherapeutics San Diego, CA	ulcerative colitis	Phase II www.sphbio.com
Stelara® ustekinumab	Janssen Research & Development Raritan, NJ	Crohn's disease (pediatric) ulcerative colitis (pediatric)	Phase III www.janssen.com
SZN-1326 (Wnt signaling pathway stimulant)	Surrozen South San Francisco, CA	inflammatory bowel disease	Phase I www.surrozen.com
Tremfya® guselkumab	Janssen Research & Development Raritan, NJ	Crohn's disease, ulcerative colitis, Crohn's disease (subcutaneous induction)	Phase III www.janssen.com
umbilical cord-derived allogeneic mesenchymal stem cell therapy	Vitro Biopharma Golden, CO	Crohn's disease	Phase I/II www.vitrobiopharma.com
Vibrezi® eluxadoline	AbbVie North Chicago, IL	irritable bowel syndrome (pediatric)	Phase III www.abbvie.com
VTX-002 (S1P1 modulator)	Ventyx Biosciences Encinitas, CA	ulcerative colitis	Phase II www.ventyxbio.com

Gastrointestinal Disorders

<u>Drug Name</u>	<u>Organization</u>	<u>Indication</u>	<u>Development Phase</u>
Xeljanz® tofacitinib	Pfizer New York, NY	ulcerative colitis (pediatric)	Phase III www.pfizer.com
Zeposia® ozanimod	Bristol-Myers Squibb Princeton, NJ	Crohn's disease	Phase III www.bms.com

Lung Disorders

<u>Drug Name</u>	<u>Organization</u>	<u>Indication</u>	<u>Development Phase</u>
ADL 018	Kashiv BioSciences Piscataway, NJ	asthma	Phase I www.kashivbiosciences.com
AMB-05X (anti-CSF1R mAb)	AmMax Bio redwood City, CA	idiopathic pulmonary fibrosis	Phase II www.ammx.bio
amlitelimab (anti-OX40L mAb)	Sanofi Bridgewater, NJ	asthma	Phase II www.sanofi.com
ANG-3070 (tyrosine kinase inhibitor)	Angion Biomedica San Francisco, CA	idiopathic pulmonary fibrosis	Phase I www.angion.com
ARO-MUC5AC (mucin inhibitor)	Arrowhead Pharmaceuticals Pasadena, CA	asthma	Phase I www.arrowheadpharma.com

Lung Disorders

<u>Drug Name</u>	<u>Organization</u>	<u>Indication</u>	<u>Development Phase</u>
ARO-RAGE (RAGE antagonist)	Arrowhead Pharmaceuticals Pasadena, CA	asthma	Phase I www.arrowheadpharma.com
astegolimab (RG6149) (anti-ST2 mAb)	Roche/Genentech South San Francisco, CA	chronic obstructive pulmonary disease (COPD)	Phase II www.roche.com
Aectura® indacaterol/mometasone	Novartis Pharmaceuticals East Hanover, NJ	asthma (pediatric)	Phase II www.novartis.com
AVTX-002 (anti-LIGHT mAb)	Avalo Therapeutics Wayne, PA	non-eosinophilic asthma	Phase II www.avalotx.com
AZD1402 (IL-4 receptor antagonist)	AstraZeneca Wilmington, DE	asthma	Phase II www.astrazeneca.com
AZD4604 (JAK inhibitor)	AstraZeneca Wilmington, DE	asthma	Phase I www.astrazeneca.com
AZD5055 (PORCN protein inhibitor)	AstraZeneca Wilmington, DE	idiopathic pulmonary fibrosis	Phase I www.astrazeneca.com
AZD5718 (5-lipoxygenase activating protein inhibitor)	AstraZeneca Wilmington, DE	asthma	Phase II www.astrazeneca.com

Lung Disorders

<u>Drug Name</u>	<u>Organization</u>	<u>Indication</u>	<u>Development Phase</u>
AZD7986 (DPP1 inhibitor)	AstraZeneca Wilmington, DE	COPD	Phase II www.astrazeneca.com
AZD8630 (AMG 104) (TSLP inhibitor)	Amgen Thousand Oaks, CA AstraZeneca Wilmington, DE	asthma	Phase I www.astrazeneca.com
BI 1015550 (PDE4B inhibitor)	Boehringer Ingelheim Ridgefield, CT	idiopathic pulmonary fibrosis (Breakthrough Therapy)	Phase II completed www.boehringer-ingelheim.com
BI 1839100	Boehringer Ingelheim Ridgefield, CT	pulmonary fibrosis	Phase I www.boehringer-ingelheim.com
BMS-986278 (LPA1 receptor antagonist)	Bristol-Myers Squibb Princeton, NJ	pulmonary fibrosis	Phase II www.bms.com
Breztri Aerospere® budesonide, glycopyrrolate, formoterol fumarate inhaled aerosol	AstraZeneca Wilmington, DE	asthma	Phase III www.astrazeneca.com
CBP-201 (IL-4 receptor antagonist)	Connect Biopharma San Diego, CA	asthma	Phase II www.connectbiopharm.com

Lung Disorders

<u>Drug Name</u>	<u>Organization</u>	<u>Indication</u>	<u>Development Phase</u>
CHF 5993 + CHF 1535 (beclometasone/formoterol/ glycopyrrolate fixed-dose combination)	Chiesi Farmaceutici Parma, Italy	COPD	Phase III www.chiesi.com
CSJ117 (TSLP inhibitor)	Novartis Pharmaceuticals East Hanover, NJ	asthma, COPD	Phase II www.novartis.com
CSL311 (anti-beta common mAb)	CSL Behring King of Prussia, PA	asthma	Phase I www.csl.com
CSL312 (garadacimab) (factor XIIa inhibitor)	CSL Behring King of Prussia, PA	idiopathic pulmonary fibrosis	Phase II www.csl.com
cudetaxestat (ENPP2 protein inhibitor) ORPHAN DRUG	Blade Therapeutics South San Francisco, CA	idiopathic pulmonary fibrosis	Phase II www.blademed.com
depemokimab (long acting IL-5 antagonist)	GlaxoSmithKline Research Triangle Park, NC	asthma	Phase III www.gsk.com
dexpramipexole (IL-13/IL-4 inhibitor)	Knopp Biosciences Pittsburgh, PA	asthma	Phase II www.knoppbio.com

Lung Disorders

<u>Drug Name</u>	<u>Organization</u>	<u>Indication</u>	<u>Development Phase</u>
Dupixent® dupilumab	Regeneron Tarrytown, NY Sanofi Bridgewater, NJ	COPD	Phase III www.regeneron.com www.sanofi.com
ensifentrine (PDE inhibitor)	Verona Pharma Raleigh, NC	COPD	Phase III www.veronapharma.com
ENV-101 (hedgehog inhibitor)	Endeavor BioMedicines San Diego, CA	idiopathic pulmonary fibrosis	Phase II www.endeavorbiomedicines.com
Fasenra® benralizumab	AstraZeneca Wilmington, DE	COPD	Phase III www.astrazeneca.com
GB0139 (galectin 3 inhibitor) ORPHAN DRUG	Galecto Biotech Copenhagen, Denmark	idiopathic pulmonary fibrosis	Phase II www.galecto.com
GSK3923868 (PI4K inhibitor)	GlaxoSmithKline Research Triangle Park, NC	COPD	Phase I www.gsk.com
HZN-825 (lysophosphatidic acid receptor antagonists)	Horizon Therapeutics Deerfield, IL	idiopathic pulmonary fibrosis	Phase II www.horizontherapeutics.com

Lung Disorders

<u>Drug Name</u>	<u>Organization</u>	<u>Indication</u>	<u>Development Phase</u>
IM156 (OXPHOS inhibitor/AMPK activator) ORPHAN DRUG	ImmunoMet Therapeutics Houston, TX	idiopathic pulmonary fibrosis (Fast Track)	Phase I completed www.immunomet.com
INOpulse® nitric oxide inhalation	Bellerophon Therapeutics Warren, NJ	COPD	Phase II www.bellerophon.com
interferon gamma-primed mesenchymal stem cell therapy	Ossium Health San Francisco, CA	asthma	Phase I www.ossiumhealth.com
IP01 (pirfenidone inhalation) ORPHAN DRUG	Avalyn Pharma Seattle, WA	idiopathic pulmonary fibrosis	Phase I/II www.avalynpharma.com
ISM001-005	InSilico Medicine New York, NY	idiopathic pulmonary fibrosis	Phase I www.insilico.com
itepekimab (anti-IL-33 mAb)	Regeneron Tarrytown, NY Sanofi Bridgewater, NJ	COPD	Phase III www.regeneron.com www.sanofi.com
KN-002 (JAK inhibitor)	Kinaset Therapeutics Boston, MA	severe asthma	Phase I www.kinasettherapeutics.com

Lung Disorders

<u>Drug Name</u>	<u>Organization</u>	<u>Indication</u>	<u>Development Phase</u>
LTI-03 (caveolin-1 replacement)	Lung Therapeutics Austin, TX	idiopathic pulmonary fibrosis	Phase I www.lungtx.com
LYT-100 (deupirfenidone)	PureTech Health Boston, MA	idiopathic pulmonary fibrosis	Phase II www.puretechhealth.com
MN-001 (tipelukast) (anti-inflammatory/anti-fibrotic) ORPHAN DRUG	MediciNova La Jolla, CA	idiopathic pulmonary fibrosis (Fast Track)	Phase II www.medicinova.com
MRx-4DP0004 (live biotherapeutic product)	4D Pharma Leeds, United Kingdom	asthma	Phase I/II www.4dpharmapl.com
navafenterol (muscarinic antagonist/ beta-2 agonist)	AstraZeneca Wilmington, DE	COPD	Phase II www.astrazeneca.com
Nucala [®] mepolizumab	GlaxoSmithKline Research Triangle Park, NC	COPD	Phase III www.gsk.com
olitigaltin (GB0139) (inhaled galectin 3 inhibitor) ORPHAN DRUG	Galecto Copenhagen, Denmark	idiopathic pulmonary fibrosis	Phase II www.galecto.com

Lung Disorders

<u>Drug Name</u>	<u>Organization</u>	<u>Indication</u>	<u>Development Phase</u>
ORIN1001 (ERN2 protein inhibitor)	Orinove Newbury Park, CA	idiopathic pulmonary fibrosis	Phase I www.orinove.com
pamrevlumab (connective tissue growth factor inhibitor) ORPHAN DRUG	FibroGen San Francisco, CA	idiopathic pulmonary fibrosis (Fast Track)	Phase III www.fibrogen.com
PLN-74809 (alphaVbeta1/alphaVbeta6 inhibitor) ORPHAN DRUG	Pliant Therapeutics South San Francisco, CA	idiopathic pulmonary fibrosis (Fast Track)	Phase II www.pliantrx.com
PT027 (albuterol/budesonide FDC)	AstraZeneca Wilmington, DE Avillion London, United Kingdom	asthma	application submitted www.astrazeneca.com
QBW251 (icenticaftor) (CFTR potentiator)	Novartis Pharmaceuticals East Hanover, NJ	COPD	Phase II www.novartis.com
quisovalimab (AVTX-002) (anti-LIGHT mAb)	Avalo Therapeutics Wayne, NJ	non-eosinophilic asthma	Phase II www.avalotx.com
RG6341	Roche/Genentech South San Francisco, CA	asthma	Phase I www.roche.com

Lung Disorders

<u>Drug Name</u>	<u>Organization</u>	<u>Indication</u>	<u>Development Phase</u>
rilzabrutinib (BTK inhibitor)	Sanofi Bridgewater, NJ	asthma	Phase II www.sanofi.com
rodatristat ethyl (tryptophan hydroxylase inhibitor)	Altavant Sciences Cary, NC	idiopathic pulmonary fibrosis	Phase I www.altavant.com
RP5063 (brilaroxazine)	Reviva Pharmaceuticals Cupertino, CA	idiopathic pulmonary fibrosis	Phase I www.revivapharma.com
RPT193 (CCR4 receptor antagonist)	RAPT Therapeutics South San Francisco, CA	asthma	Phase I www.rapt.com
SAR443765 (IL13/TSLP inhibitor)	Sanofi Bridgewater, NJ	asthma	Phase I www.sanofi.com
SelK2 (P-selectin ligand protein inhibitor)	Tetherex Pharmaceuticals Oklahoma City, OK	asthma, COPD	Phase II www.tetherex.com
Tezspire® tezepelumab-ekko	Amgen Thousand Oaks, CA AstraZeneca Wilmington, DE	COPD	Phase III www.astrazeneca.com

Lung Disorders

<u>Drug Name</u>	<u>Organization</u>	<u>Indication</u>	<u>Development Phase</u>
tozorakimab (IL-33 inhibitor)	AstraZeneca Wilmington, DE	COPD	Phase III www.astrazeneca.com
		asthma	Phase II www.astrazeneca.com
Tyvaso [®] treprostinil ORPHAN DRUG	United Therapeutics Silver Spring, MD	idiopathic pulmonary fibrosis	Phase III www.unither.com
UPB-101 (TSLP modulator)	Upstream Biosciences Waltham, MA	asthma	Phase I www.upstreambio.com
zinpentraxin alfa (RG6354) (TGF beta-1 modulator) ORPHAN DRUG	Roche/Genentech South San Francisco, CA	idiopathic pulmonary fibrosis (Breakthrough Therapy)	Phase III www.roche.com
zofin (nanoparticle-based therapeutic)	Organicell Miami, FL	COPD	Phase I/II www.organicell.com

Obesity

<u>Drug Name</u>	<u>Organization</u>	<u>Indication</u>	<u>Development Phase</u>
AMG 133 (GIPR antagonist/GLP1 agonist)	Amgen Thousand Oaks, CA	obesity	Phase I www.amgen.com
AMG 786 (small molecule)	Amgen Thousand Oaks, CA	obesity	Phase I www.amgen.com
amylin agonist long acting	Lilly Indianapolis, IN	obesity	Phase I www.lilly.com
ARD-101 (G protein-coupled receptor agonist)	Aardvark Therapeutics San Diego, CA	obesity	Phase II www.aardvarktherapeutics.com
BI 456906 (GLP1/GCGR agonist)	Boehringer Ingelheim Ridgefield, CT	obesity	Phase II www.boehringer-ingelheim.com
CagriSema (amylin analogue/GLP1 analogue)	Novo Nordisk Plainsboro, NJ	obesity	Phase I www.novonordisk.com
CB4211 (lipolysis inhibitor)	CohBar Menlo Park, CA	obesity	Phase I www.cohbar.com
CBL-514 injection (lipid modulator)	Caliway Biopharmaceuticals New Taipei City, Taiwan	non-surgical fat reduction	Phase II www.caliway.com.tw

Obesity

<u>Drug Name</u>	<u>Organization</u>	<u>Indication</u>	<u>Development Phase</u>
CIN-109 (GDF-15 analog)	CinFina Pharma (CinRx) Cincinnati, OH	obesity	Phase I www.cinrx.com
CIN-110 (PYY analog)	CinFina Pharma (CinRx) Cincinnati, OH	obesity	Phase I www.cinrx.com
CIN-209 (GLP1/GDF-15 dual agonist)	CinFina Pharma (CinRx) Cincinnati, OH	obesity	Phase I www.cinrx.com
CIN-110 (GLP/PYY dual agonist)	CinFina Pharma (CinRx) Cincinnati, OH	obesity	Phase I www.cinrx.com
cotadutide (GLP1/glucagon receptor agonist)	AstraZeneca Wilmington, DE	obesity	Phase II www.astrazeneca.com
CT-388 (GLP1/GIP dual receptor modulator)	Carmot Therapeutics Berkeley, CA	obesity	Phase I www.carmot-therapeutics.us
DACRA QW II	Lilly Indianapolis, IN	obesity	Phase I www.lilly.com
danuglipron (PF-06882961) (GLP1R agonist)	Pfizer New York, NY	obesity	Phase II www.pfizer.com

Obesity

<u>Drug Name</u>	<u>Organization</u>	<u>Indication</u>	<u>Development Phase</u>
DD01 (GLP1/GCGR dual agonist)	Neuraly Gaithersburg, MD	obesity in patients with type 1 diabetes and NAFLD	Phase I www.neuralymed.com
ERX-1000 (leptin sensitizer)	ERX Pharmaceuticals Cambridge, MA	obesity	Phase I www.erxpharmaceuticals.com
LA-GDF15 (long acting GDF15 analogue)	Novo Nordisk Plainsboro, NJ	obesity	Phase I www.novonordisk.com
LY3437943 (retatrutide) (GGG tri-agonist)	Lilly Indianapolis, IN	obesity	Phase II www.lilly.com
LY3502970 (GLP1 receptor NPA)	Lilly Indianapolis, IN	obesity	Phase II www.lilly.com
MBL949	Novartis East Hanover, NJ	obesity-related diseases	Phase II www.novartis.com
Mounjaro [®] tirzepatide	Lilly Indianapolis, IN	obesity	Phase III www.lilly.com
NO-13065	Otsuka Pharmaceutical Factory Tokushima, Japan	obesity	Phase I www.otsuka.com

Obesity

<u>Drug Name</u>	<u>Organization</u>	<u>Indication</u>	<u>Development Phase</u>
NS-0200 (leucine-metformin combination)	NuSirt Biopharma Nashville, TN	obesity	Phase II completed www.nusirt.com
OPK8803 (GLP1/glucagon receptor agonist)	OPKO Health Miami, FL	obesity	Phase II www.opko.com
pemvidutide (GLP1/glucagon receptor co-agonist)	Altimune Gaithersburg, MD	obesity	Phase II www.altimmune.com
PYY 1875 (appetite-regulating hormone analogue)	Novo Nordisk Plainsboro, NJ	obesity	Phase II www.novonordisk.com
S-309309 (monoacylglycerol acyltransferase 2 inhibitor)	Shionogi Florham Park, NJ	obesity	Phase I www.shionogi.com
Saxenda [®] liraglutide	Novo Nordisk Plainsboro, NJ	obesity (ages 6 to 12 years)	Phase III www.novonordisk.com
semaglutide oral (long-acting GLP1 analogue)	Novo Nordisk Plainsboro, NJ	obesity	Phase III www.novonordisk.com
Yso1 (<i>Christensenella minuta</i> biotherapy)	YSOPIA Bioscience Bordeaux, France	obesity	Phase I completed www.ysopia.bio

The content of this report has been obtained through public, government and industry sources, and the Springer "Adis Insight" database based on the latest information. Report current as of **August 17, 2022**. The medicines in this listing include medicines being developed by U.S.-based companies conducting trials in the United States and abroad, PhRMA-member companies conducting trials in the United States and abroad, and foreign companies conducting clinical trials in the United States. Some products may not be in active clinical trials. The information may not be comprehensive. For more, specific information about a particular product, contact the individual company directly or go to www.clinicaltrials.gov. The entire series of *Medicines in Development* is available on PhRMA's website: www.phrma.org.

Definitions

Application Submitted—An application for marketing has been submitted by the company to the U.S. Food and Drug Administration (FDA).

Breakthrough Therapy—Upon request by a sponsor, the FDA can grant this designation to expedite the development and review of a drug or biologic intended, alone or in combination with one or more other drugs, to treat a serious or life threatening disease or condition and preliminary clinical evidence indicates that it may demonstrate substantial improvement over existing therapies on one or more clinically-significant endpoints, such as substantial treatment effects observed early in clinical development. If a drug or biologic is designated as a Breakthrough Therapy, the FDA will expedite the development and review. With this designation, all Fast Track features convey to the medicine.

Fast Track—Upon request by a sponsor, the FDA can grant this designation to facilitate the development and expedite the review of a drug or biologic to treat a serious condition and fill an unmet medical need. When considering a biopharmaceutical company's request for Fast Track designation for an investigational drug or biologic, the FDA evaluates whether it will affect factors such as survival, day-to-day functioning, or the likelihood that the disease, if left untreated, will progress from a less severe condition to a more serious one, and whether a condition can be adequately addressed by available therapy. With Fast Track designation, early and frequent communication between the FDA and the biopharmaceutical company is encouraged throughout the entire drug development and review process to help to quickly resolve any questions or issues that arise, potentially leading to an earlier approval and access by patients.

Orphan Designation—Upon request by a sponsor, the FDA can grant special status ("orphan status") to a drug or biologic to treat a rare disease or condition. In order to receive an orphan designation, a qualifying drug or biologic must be intended for the treatment, diagnosis, or prevention of a rare disease or condition that affects usually fewer than 200,000 people in the United States.

Phase I—Researchers test the investigational drug or biologic in a small group of people, usually between 20 and 100 healthy adult volunteers, to evaluate its initial safety and tolerability profile, determine a safe dosage range, and identify potential side effects.

Phase II—The investigational drug or biologic is given to volunteer patients, usually between 100 and 500, to determine whether it is effective, identify an optimal dose, and to further evaluate its short-term safety.

Phase III—The investigational drug or biologic is given to a larger, more diverse patient population, often involving between 1,000 and 5,000 patients (but sometimes many more), to generate statistically significant evidence to confirm its safety and effectiveness. Phase III studies are the longest studies and usually take place in multiple sites around the world.